Update on recent advances in amyotrophic lateral sclerosis.

Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9:617–628

pubmed: 24126629 doi: 10.1038/nrneurol.2013.203

Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, Zhan S, Wang S (2020) Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol 267:944–953

pubmed: 31797084 doi: 10.1007/s00415-019-09652-y

Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A (2016) Recent advances in amyotrophic lateral sclerosis. J Neurol 263:1241–1254

pubmed: 27025851 pmcid: 4893385 doi: 10.1007/s00415-016-8091-6

Lloyd-Sherlock P (2000) Population ageing in developed and developing regions: implications for health policy. Soc Sci Med 51:887–895

pubmed: 10972432 doi: 10.1016/S0277-9536(00)00068-X

Marin B, Boumédiene F, Logroscino G, Couratier P, Babron M-C, Leutenegger AL, Copetti M, Preux P-M, Beghi E (2017) Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 46:57–74

pubmed: 27185810

Wolfson C, Gauvin DE, Ishola F, Oskoui M (2023) Global prevalence and incidence of amyotrophic lateral sclerosis: a systematic review. Neurology 101:e613–e623

pubmed: 37308302 doi: 10.1212/WNL.0000000000207474

McFarlane R, Peelo C, Galvin M, Heverin M, Hardiman O (2023) Epidemiologic trends of amyotrophic lateral sclerosis in Ireland, 1996–2021. Neurology 101:e1905–e1912

pubmed: 37748881 doi: 10.1212/WNL.0000000000207797

Hanhisuanto M, Solje E, Jokela M, Sipilä JOT (2023) Amyotrophic Lateral Sclerosis in Southwestern and Eastern Finland. Neuroepidemiology 57:238–245

pubmed: 37399804 doi: 10.1159/000531238

Leighton DJ, Newton J, Stephenson LJ, Colville S, Davenport R, Gorrie G, Morrison I, Swingler R, Chandran S, Pal S, Consortium C-M (2019) Changing epidemiology of motor neurone disease in Scotland. J Neurol 266:817–825

pubmed: 30805795 doi: 10.1007/s00415-019-09190-7

Gianferrari G, Martinelli I, Zucchi E, Simonini C, Fini N, Vinceti M, Ferro S, Gessani A, Canali E, Valzania F, Sette E, Pugliatti M, Tugnoli V, Zinno L, Stano S, Santangelo M, De Pasqua S, Terlizzi E, Guidetti D, Medici D, Salvi F, Liguori R, Vacchiano V, Casmiro M, Querzani P, Currò Dossi M, Patuelli A, Morresi S, Longoni M, De Massis P, Rinaldi R, Borghi A, Amedei A, Mandrioli J (2022) Epidemiological, clinical and genetic features of als in the last decade: a prospective population-based study in the Emilia Romagna Region of Italy. Biomedicines 10:819

pubmed: 35453569 pmcid: 9031824 doi: 10.3390/biomedicines10040819

Chiò A, Mora G, Moglia C, Manera U, Canosa A, Cammarosano S, Ilardi A, Bertuzzo D, Bersano E, Cugnasco P, Grassano M, Pisano F, Mazzini L, Calvo A, Piemonte VD, Register for ALS (2017) Secular trends of amyotrophic lateral sclerosis: the piemonte and Valle d’Aosta Register. JAMA Neurol 74:1097–1104

pubmed: 28692730 pmcid: 5710181 doi: 10.1001/jamaneurol.2017.1387

Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH (2018) Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 17:423–433

pubmed: 29598923 doi: 10.1016/S1474-4422(18)30089-9

Domi T, Schito P, Sferruzza G, Russo T, Pozzi L, Agosta F, Carrera P, Riva N, Filippi M, Quattrini A, Falzone YM (2023) Unveiling the SOD1-mediated ALS phenotype: insights from a comprehensive meta-analysis. J Neurol

Rosenbohm A, Liu M, Nagel G, Peter RS, Cui B, Li X, Kassubek J, Rothenbacher D, Lule D, Cui L, Ludolph AC, Group ALSRSS (2018) Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol 265:774–782

pubmed: 29392461 doi: 10.1007/s00415-018-8735-9

Velez-Go MB, Perna A, Vazquez C, Ketzoian C, Lillo P, Godoy-Reyes G, Saez D, Zaldivar Vaillant T, Gutierrez Gil JV, Lara-Fernandez GE, Povedano M, Heverin M, McFarlane R, Logroscino G, Hardiman O (2023) LAENALS: epidemiological and clinical features of amyotrophic lateral sclerosis in Latin America. Amyotrophic Lateral Sclerosis Frontotemporal Degener:1–9

Logroscino G, Traynor BJ, Hardiman O, Chio A, Couratier P, Mitchell JD, Swingler RJ, Beghi E, Eurals F (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79:6–11

pubmed: 18079297 doi: 10.1136/jnnp.2006.104828

Fontana A, Marin B, Luna J, Beghi E, Logroscino G, Boumediene F, Preux PM, Couratier P, Copetti M (2021) Time-trend evolution and determinants of sex ratio in amyotrophic lateral sclerosis: a dose-response meta-analysis. J Neurol 268:2973–2984

pubmed: 33630135 doi: 10.1007/s00415-021-10464-2

Schito P, Ceccardi G, Calvo A, Falzone YM, Moglia C, Lunetta C, Marinou K, Ticozzi N, Scialo C, Sorarù G, Trojsi F, Conte A, Tortelli R, Russo M, Zucchi E, Pozzi L, Domi T, Carrera P, Agosta F, Quattrini A, Fazio R, Chiò A, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Tedeschi G, Sabatelli M, Logroscino G, Messina S, Mandrioli J, Riva N, Filippi M (2020) Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. J Neurol Neurosurg Psychiatry 91:1001–1003

pubmed: 32651246 doi: 10.1136/jnnp-2020-323542

Schito P, Russo T, Domi T, Mandelli A, Pozzi L, Carro UD, Carrera P, Agosta F, Quattrini A, Furlan R, Filippi M, Riva N (2023) Clinical features and biomarkers to differentiate primary and amyotrophic lateral sclerosis in patients with an upper motor neuron syndrome. Neurology

Schito P, Spinelli EG, Malvaso A, Russo T, Falzone YM, Agosta F, Quattrini A, Filippi M, Riva N (2022) Primary lateral sclerosis presenting with focal onset spreading through contiguous neuroanatomic regions. Neurology 98:503–504

pubmed: 35131910 doi: 10.1212/WNL.0000000000200011

Chiò A, Moglia C, Canosa A, Manera U, D’Ovidio F, Vasta R, Grassano M, Brunetti M, Barberis M, Corrado L, D’Alfonso S, Iazzolino B, Peotta L, Sarnelli MF, Solara V, Zucchetti JP, De Marchi F, Mazzini L, Mora G, Calvo A (2020) ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology 94:e802–e810

pubmed: 31907290 doi: 10.1212/WNL.0000000000008869

Grassano M, Moglia C, Palumbo F, Koumantakis E, Cugnasco P, Callegaro S, Canosa A, Manera U, Vasta R, De Mattei F, Matteoni E, Fuda G, Salamone P, Marchese G, Casale F, De Marchi F, Mazzini L, Mora G, Calvo A, Chio A (2024) Sex differences in amyotrophic lateral sclerosis survival and progression: a multidimensional analysis. Ann Neurol

Bede P, Elamin M, Byrne S, Hardiman O (2014) Sexual dimorphism in ALS: exploring gender-specific neuroimaging signatures. Amyotrophic Lateral Sclerosis Frontotemporal Degener 15:235–243

doi: 10.3109/21678421.2013.865749

Trojsi F, Di Nardo F, Caiazzo G, Siciliano M, D’Alvano G, Passaniti C, Russo A, Bonavita S, Cirillo M, Esposito F, Tedeschi G (2021) Between-sex variability of resting state functional brain networks in amyotrophic lateral sclerosis (ALS). J Neural Transm 128:1881–1897

pubmed: 34471976 doi: 10.1007/s00702-021-02413-0

Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G (2022) Amyotrophic lateral sclerosis. Lancet 400:1363–1380

pubmed: 36116464 pmcid: 10089700 doi: 10.1016/S0140-6736(22)01272-7

van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH (2017) Amyotrophic lateral sclerosis. Lancet 390:2084–2098

pubmed: 28552366 doi: 10.1016/S0140-6736(17)31287-4

Zhou W, Xu R (2023) Current insights in the molecular genetic pathogenesis of amyotrophic lateral sclerosis. Front Neurosci 17:1189470

pubmed: 37638324 pmcid: 10448825 doi: 10.3389/fnins.2023.1189470

Muzio L, Sirtori R, Gornati D, Eleuteri S, Fossaghi A, Brancaccio D, Manzoni L, Ottoboni L, Feo L, Quattrini A, Mastrangelo E, Sorrentino L, Scalone E, Comi G, Marinelli L, Riva N, Milani M, Seneci P, Martino G (2020) Retromer stabilization results in neuroprotection in a model of Amyotrophic Lateral Sclerosis. Nat Commun 11:3848

pubmed: 32737286 pmcid: 7395176 doi: 10.1038/s41467-020-17524-7

Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O’Regan JP, Deng HX et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62

pubmed: 8446170 doi: 10.1038/362059a0

Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:1668–1672

pubmed: 18309045 pmcid: 7116650 doi: 10.1126/science.1154584

Chen Y, Li S, Su L, Sheng J, Lv W, Chen G, Xu Z (2015) Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. J Neurol 262:814–822

pubmed: 25578179 doi: 10.1007/s00415-014-7630-2

Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Holtta-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chio A, Restagno G, Borghero G, Sabatelli M, Consortium I, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257-268

DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256

pubmed: 21944778 pmcid: 3202986 doi: 10.1016/j.neuron.2011.09.011

Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A, Restagno G, Nicolaou N, Simon-Sanchez J, van Swieten JC, Abramzon Y, Johnson JO, Sendtner M, Pamphlett R, Orrell RW, Mead S, Sidle KC, Houlden H, Rohrer JD, Morrison KE, Pall H, Talbot K, Ansorge O, Chromosome ALSFTDC, French research network on FFA, Consortium I, Hernandez DG, Arepalli S, Sabatelli M, Mora G, Corbo M, Giannini F, Calvo A, Englund E, Borghero G, Floris GL, Remes AM, Laaksovirta H, McCluskey L, Trojanowski JQ, Van Deerlin VM, Schellenberg GD, Nalls MA, Drory VE, Lu CS, Yeh TH, Ishiura H, Takahashi Y, Tsuji S, Le Ber I, Brice A, Drepper C, Williams N, Kirby J, Shaw P, Hardy J, Tienari PJ, Heutink P, Morris HR, Pickering-Brown S, Traynor BJ (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11:323-330

Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, Sidle K, Fratta P, Orrell RW, Hardy J, Holton J, Revesz T, Rossor MN, Warren JD (2015) C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 14:291–301

pubmed: 25638642 doi: 10.1016/S1474-4422(14)70233-9

Silverman JM, Fernando SM, Grad LI, Hill AF, Turner BJ, Yerbury JJ, Cashman NR (2016) Disease mechanisms in ALS: misfolded SOD1 transferred through exosome-dependent and exosome-independent pathways. Cell Mol Neurobiol 36:377–381

pubmed: 26908139 doi: 10.1007/s10571-015-0294-3

Bagyinszky E, Hulme J, An SSA (2023) Studies of Genetic and Proteomic Risk Factors of Amyotrophic Lateral Sclerosis Inspire Biomarker Development and Gene Therapy. Cells 12

Bartoletti-Stella A, Vacchiano V, De Pasqua S, Mengozzi G, De Biase D, Bartolomei I, Avoni P, Rizzo G, Parchi P, Donadio V, Chio A, Pession A, Oppi F, Salvi F, Liguori R, Capellari S, BoReAls (2021) Targeted sequencing panels in Italian ALS patients support different etiologies in the ALS/FTD continuum. J Neurol 268:3766–3776

pubmed: 33770234 pmcid: 8463338 doi: 10.1007/s00415-021-10521-w

McCann EP, Grima N, Fifita JA, Chan Moi Fat S, Lehnert K, Henden L, Blair IP, Williams KL (2023) Characterising the genetic landscape of amyotrophic lateral sclerosis: a catalogue and assessment of over 1,000 published genetic variants. J Neuromuscular Dis 10:1127–1141

doi: 10.3233/JND-230148

Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu YF, Wang Q, Krueger BJ, Ren Z, Keebler J, Han Y, Levy SE, Boone BE, Wimbish JR, Waite LL, Jones AL, Carulli JP, Day-Williams AG, Staropoli JF, Xin WW, Chesi A, Raphael AR, McKenna-Yasek D, Cady J, Vianney de Jong JM, Kenna KP, Smith BN, Topp S, Miller J, Gkazi A, Consortium FS, Al-Chalabi A, van den Berg LH, Veldink J, Silani V, Ticozzi N, Shaw CE, Baloh RH, Appel S, Simpson E, Lagier-Tourenne C, Pulst SM, Gibson S, Trojanowski JQ, Elman L, McCluskey L, Grossman M, Shneider NA, Chung WK, Ravits JM, Glass JD, Sims KB, Van Deerlin VM, Maniatis T, Hayes SD, Ordureau A, Swarup S, Landers J, Baas F, Allen AS, Bedlack RS, Harper JW, Gitler AD, Rouleau GA, Brown R, Harms MB, Cooper GM, Harris T, Myers RM, Goldstein DB (2015) Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347:1436-1441

Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Muller K, Marroquin N, Nordin F, Hubers A, Weydt P, Pinto S, Press R, Millecamps S, Molko N, Bernard E, Desnuelle C, Soriani MH, Dorst J, Graf E, Nordstrom U, Feiler MS, Putz S, Boeckers TM, Meyer T, Winkler AS, Winkelman J, de Carvalho M, Thal DR, Otto M, Brannstrom T, Volk AE, Kursula P, Danzer KM, Lichtner P, Dikic I, Meitinger T, Ludolph AC, Strom TM, Andersen PM, Weishaupt JH (2015) Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci 18:631–636

pubmed: 25803835 doi: 10.1038/nn.4000

Brenner D, Muller K, Wieland T, Weydt P, Bohm S, Lule D, Hubers A, Neuwirth C, Weber M, Borck G, Wahlqvist M, Danzer KM, Volk AE, Meitinger T, Strom TM, Otto M, Kassubek J, Ludolph AC, Andersen PM, Weishaupt JH (2016) NEK1 mutations in familial amyotrophic lateral sclerosis. Brain J Neurol 139:e28

doi: 10.1093/brain/aww033

Pozzi L, Valenza F, Mosca L, Dal Mas A, Domi T, Romano A, Tarlarini C, Falzone YM, Tremolizzo L, Soraru G, Cerri F, Ferraro PM, Basaia S, Agosta F, Fazio R, Comola M, Comi G, Ferrari M, Quattrini A, Lunetta C, Penco S, Bonanomi D, Carrera P, Riva N (2017) TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation. J Neurol Neurosurg Psychiatry 88:869–875

pubmed: 28822984 doi: 10.1136/jnnp-2017-316174

Riva N, Pozzi L, Russo T, Pipitone GB, Schito P, Domi T, Agosta F, Quattrini A, Carrera P, Filippi M (2022) NEK1 variants in a cohort of italian patients with amyotrophic lateral sclerosis. Front Neurosci 16:833051

pubmed: 35495032 pmcid: 9048593 doi: 10.3389/fnins.2022.833051

Fellner A, Goldberg Y, Basel-Salmon L (2023) Ordering genetic testing by neurologists: points to consider. J Neurol 270:3714–3722

pubmed: 37154893 doi: 10.1007/s00415-023-11758-3

Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R, Brown P, Ravenscroft T, van Blitterswijk M, Nicholson AM, DeTure M, Knopman DS, Josephs KA, Parisi JE, Petersen RC, Boylan KB, Boeve BF, Graff-Radford NR, Veltman JA, Gilissen C, Murray ME, Dickson DW, Rademakers R (2015) Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol 130:77–92

pubmed: 25943890 pmcid: 4470809 doi: 10.1007/s00401-015-1436-x

Lattante S, Doronzio PN, Marangi G, Conte A, Bisogni G, Bernardo D, Russo T, Lamberti D, Patrizi S, Apollo FP, Lunetta C, Scarlino S, Pozzi L, Zollino M, Riva N, Sabatelli M (2019) Coexistence of variants in TBK1 and in other ALS-related genes elucidates an oligogenic model of pathogenesis in sporadic ALS. Neurobiol Aging 84:239 e239–239 e214

Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G, Cannas A, Occhineri P, Cau TB, Loi D, Ticca A, Traccis S, Manera U, Canosa A, Moglia C, Calvo A, Barberis M, Brunetti M, Gibbs JR, Renton AE, Errichiello E, Zoledziewska M, Mulas A, Qian Y, Din J, Pliner HA, Traynor BJ, Chio A, Italsgen CS (2016) TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiol Aging 43(180):e181-185

Kenna KP, van Doormaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, van Rheenen W, van Eijk KR, Jones AR, Keagle P, Shatunov A, Sproviero W, Smith BN, van Es MA, Topp SD, Kenna A, Miller JW, Fallini C, Tiloca C, McLaughlin RL, Vance C, Troakes C, Colombrita C, Mora G, Calvo A, Verde F, Al-Sarraj S, King A, Calini D, de Belleroche J, Baas F, van der Kooi AJ, de Visser M, Ten Asbroek AL, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Munoz-Blanco JL, Strom TM, Meitinger T, Morrison KE, Consortium S, Lauria G, Williams KL, Leigh PN, Nicholson GA, Blair IP, Leblond CS, Dion PA, Rouleau GA, Pall H, Shaw PJ, Turner MR, Talbot K, Taroni F, Boylan KB, Van Blitterswijk M, Rademakers R, Esteban-Perez J, Garcia-Redondo A, Van Damme P, Robberecht W, Chio A, Gellera C, Drepper C, Sendtner M, Ratti A, Glass JD, Mora JS, Basak NA, Hardiman O, Ludolph AC, Andersen PM, Weishaupt JH, Brown RH, Jr., Al-Chalabi A, Silani V, Shaw CE, van den Berg LH, Veldink JH, Landers JE (2016) NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature genetics 48:1037-1042

Farhan SMK, Howrigan DP, Abbott LE, Klim JR, Topp SD, Byrnes AE, Churchhouse C, Phatnani H, Smith BN, Rampersaud E, Wu G, Wuu J, Shatunov A, Iacoangeli A, Al Khleifat A, Mordes DA, Ghosh S, Consortium A, Consortium F, Project Min EC, Eggan K, Rademakers R, McCauley JL, Schule R, Zuchner S, Benatar M, Taylor JP, Nalls M, Gotkine M, Shaw PJ, Morrison KE, Al-Chalabi A, Traynor B, Shaw CE, Goldstein DB, Harms MB, Daly MJ, Neale BM (2019) Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nature neuroscience 22:1966-1974

Wang S, Zheng X, Wei Q, Lin J, Yang T, Xiao Y, Jiang Q, Li C, Shang H (2023) Rare DNAJC7 variants may play a minor role in chinese patients with ALS. Mol Neurobiol

Osmanovic A, Forster A, Widjaja M, Auber B, Das AM, Christians A, Brand F, Petri S, Weber RG (2022) A SUMO4 initiator codon variant in amyotrophic lateral sclerosis reduces SUMO4 expression and alters stress granule dynamics. J Neurol 269:4863–4871

pubmed: 35503374 pmcid: 9363285 doi: 10.1007/s00415-022-11126-7

Brenner D, Yilmaz R, Muller K, Grehl T, Petri S, Meyer T, Grosskreutz J, Weydt P, Ruf W, Neuwirth C, Weber M, Pinto S, Claeys KG, Schrank B, Jordan B, Knehr A, Gunther K, Hubers A, Zeller D, Kubisch C, Jablonka S, Sendtner M, Klopstock T, de Carvalho M, Sperfeld A, Borck G, Volk AE, Dorst J, Weis J, Otto M, Schuster J, Del Tredici K, Braak H, Danzer KM, Freischmidt A, Meitinger T, Strom TM, Ludolph AC, Andersen PM, Weishaupt JH, German ALSnMNDNET (2018) Hot-spot KIF5A mutations cause familial ALS. Brain J Neurol 141:688–697

doi: 10.1093/brain/awx370

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt J, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A, Consortium I, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L, Genomic Translation for ALSCC, Moreno CAM, Kamalakaran S, Goldstein DB, Consortium ALSS, Gitler AD, Harris T, Myers RM, Consortium NA, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC, Answer ALSF, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E, Clinical Research in ALS, Related Disorders for Therapeutic Development C, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J, Consortium S, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Soraru G, Cereda C, French ALSC, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek A, Munoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Perez J, Garcia-Redondo A, Al-Chalabi A, Project Min EALSSC, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH, Jr., van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chio A, Shaw CE, Traynor BJ, Landers JE (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97:1268-1283 e1266

Saez-Atienzar S, Dalgard CL, Ding J, Chio A, Alba C, Hupalo DN, Wilkerson MD, Bowser R, Pioro EP, Bedlack R, Traynor BJ (2020) Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. Neurology 95:1015–1018

pubmed: 33077544 pmcid: 7734922 doi: 10.1212/WNL.0000000000011064

Guo L, Mao Q, He J, Liu X, Piao X, Luo L, Hao X, Yu H, Song Q, Xiao B, Fan D, Gao Z, Jia Y (2023) Disruption of ER ion homeostasis maintained by an ER anion channel CLCC1 contributes to ALS-like pathologies. Cell Res 33:497–515

pubmed: 37142673 pmcid: 10313822 doi: 10.1038/s41422-023-00798-z

Tang L, Tang X, Zhao Q, Li Y, Bu Y, Liu Z, Li J, Guo J, Shen L, Jiang H, Tang B, Xu R, Cao W, Yuan Y, Wang J (2023) Mutation and clinical analysis of the CLCC1 gene in amyotrophic lateral sclerosis patients from Central South China. Ann Clini Transl Neurol. https://doi.org/10.1002/acn3.51934

doi: 10.1002/acn3.51934

Johnson JO, Chia R, Miller DE, Li R, Kumaran R, Abramzon Y, Alahmady N, Renton AE, Topp SD, Gibbs JR, Cookson MR, Sabir MS, Dalgard CL, Troakes C, Jones AR, Shatunov A, Iacoangeli A, Al Khleifat A, Ticozzi N, Silani V, Gellera C, Blair IP, Dobson-Stone C, Kwok JB, Bonkowski ES, Palvadeau R, Tienari PJ, Morrison KE, Shaw PJ, Al-Chalabi A, Brown RH Jr, Calvo A, Mora G, Al-Saif H, Gotkine M, Leigh F, Chang IJ, Perlman SJ, Glass I, Scott AI, Shaw CE, Basak AN, Landers JE, Chio A, Crawford TO, Smith BN, Traynor BJ, Consortium FS, American Genome C, International ALSGC, Consortium I, Smith BN, Ticozzi N, Fallini C, Gkazi AS, Topp SD, Scotter EL, Kenna KP, Keagle P, Tiloca C, Vance C, Troakes C, Colombrita C, King A, Pensato V, Castellotti B, Baas F, Ten Asbroek A, McKenna-Yasek D, McLaughlin RL, Polak M, Asress S, Esteban-Perez J, Stevic Z, D’Alfonso S, Mazzini L, Comi GP, Del Bo R, Ceroni M, Gagliardi S, Querin G, Bertolin C, van Rheenen W, Rademakers R, van Blitterswijk M, Lauria G, Duga S, Corti S, Cereda C, Corrado L, Soraru G, Williams KL, Nicholson GA, Blair IP, Leblond-Manry C, Rouleau GA, Hardiman O, Morrison KE, Veldink JH, van den Berg LH, Al-Chalabi A, Pall H, Shaw PJ, Turner MR, Talbot K, Taroni F, Garcia-Redondo A, Wu Z, Glass JD, Gellera C, Ratti A, Brown RH Jr, Silani V, Shaw CE, Landers JE, Dalgard CL, Adeleye A, Soltis AR, Alba C, Viollet C, Bacikova D, Hupalo DN, Sukumar G, Pollard HB, Wilkerson MD, Martinez EM, Abramzon Y, Ahmed S, Arepalli S, Baloh RH, Bowser R, Brady CB, Brice A, Broach J, Campbell RH, Camu W, Chia R, Cooper-Knock J, Ding J, Drepper C, Drory VE, Dunckley TL, Eicher JD, England BK, Faghri F, Feldman E, Floeter MK, Fratta P, Geiger JT, Gerhard G, Gibbs JR, Gibson SB, Glass JD, Hardy J, Harms MB, Heiman-Patterson TD, Hernandez DG, Jansson L, Kirby J, Kowall NW, Laaksovirta H, Landeck N, Landi F, Le Ber I, Lumbroso S, MacGowan DJL, Maragakis NJ, Mora G, Mouzat K, Murphy NA, Myllykangas L, Nalls MA, Orrell RW, Ostrow LW, Pamphlett R, Pickering-Brown S, Pioro EP, Pletnikova O, Pliner HA, Pulst SM, Ravits JM, Renton AE, Rivera A, Robberecht W, Rogaeva E, Rollinson S, Rothstein JD, Scholz SW, Sendtner M, Shaw PJ, Sidle KC, Simmons Z, Singleton AB, Smith N, Stone DJ, Tienari PJ, Troncoso JC, Valori M, Van Damme P, Van Deerlin VM, Van Den Bosch L, Zinman L, Landers JE, Chio A, Traynor BJ, Angelocola SM, Ausiello FP, Barberis M, Bartolomei I, Battistini S, Bersano E, Bisogni G, Borghero G, Brunetti M, Cabona C, Calvo A, Canale F, Canosa A, Cantisani TA, Capasso M, Caponnetto C, Cardinali P, Carrera P, Casale F, Chio A, Colletti T, Conforti FL, Conte A, Conti E, Corbo M, Cuccu S, Dalla Bella E, D’Errico E, DeMarco G, Dubbioso R, Ferrarese C, Ferraro PM, Filippi M, Fini N, Floris G, Fuda G, Gallone S, Gianferrari G, Giannini F, Grassano M, Greco L, Iazzolino B, Introna A, La Bella V, Lattante S, Lauria G, Liguori R, Logroscino G, Logullo FO, Lunetta C, Mandich P, Mandrioli J, Manera U, Manganelli F, Marangi G, Marinou K, Marrosu MG, Martinelli I, Messina S, Moglia C, Mora G, Mosca L, Murru MR, Origone P, Passaniti C, Petrelli C, Petrucci A, Pozzi S, Pugliatti M, Quattrini A, Ricci C, Riolo G, Riva N, Russo M, Sabatelli M, Salamone P, Salivetto M, Salvi F, Santarelli M, Sbaiz L, Sideri R, Simone I, Simonini C, Spataro R, Tanel R, Tedeschi G, Ticca A, Torriello A, Tranquilli S, Tremolizzo L, Trojsi F, Vasta R, Vacchiano V, Vita G, Volanti P, Zollino M, Zucchi E (2021) Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurol 78:1236–1248

pubmed: 34459874 doi: 10.1001/jamaneurol.2021.2598

Borghero G, Pili F, Muroni A, Ercoli T, Pateri MI, Pilotto S, Maccabeo A, Defazio G (2023) Disease survival and progression in TARDBP ALS patients from Sardinia, Italy. J Neurol

Colombo E, Poletti B, Maranzano A, Peverelli S, Solca F, Colombrita C, Torre S, Tiloca C, Verde F, Bonetti R, Carelli L, Morelli C, Ratti A, Silani V, Ticozzi N (2023) Motor, cognitive and behavioural profiles of C9orf72 expansion-related amyotrophic lateral sclerosis. J Neurol 270:898–908

pubmed: 36308529 doi: 10.1007/s00415-022-11433-z

Miltenberger-Miltenyi G, Conceicao VA, Gromicho M, Pronto-Laborinho AC, Pinto S, Andersen PM, de Carvalho M (2019) C9orf72 expansion is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 90:118–120

pubmed: 29661924 doi: 10.1136/jnnp-2018-318032

Conforti FL, Spataro R, Sproviero W, Mazzei R, Cavalcanti F, Condino F, Simone IL, Logroscino G, Patitucci A, Magariello A, Muglia M, Rodolico C, Valentino P, Bono F, Colletti T, Monsurro MR, Gambardella A, La Bella V (2012) Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology 79:2315–2320

pubmed: 23197749 doi: 10.1212/WNL.0b013e318278b618

Sproviero W, Shatunov A, Stahl D, Shoai M, van Rheenen W, Jones AR, Al-Sarraj S, Andersen PM, Bonini NM, Conforti FL, Van Damme P, Daoud H, Del Mar AM, Fogh I, Forzan M, Gaastra B, Gellera C, Gitler AD, Hardy J, Fratta P, La Bella V, Le Ber I, Van Langenhove T, Lattante S, Lee YC, Malaspina A, Meininger V, Millecamps S, Orrell R, Rademakers R, Robberecht W, Rouleau G, Ross OA, Salachas F, Sidle K, Smith BN, Soong BW, Soraru G, Stevanin G, Kabashi E, Troakes C, van Broeckhoven C, Veldink JH, van den Berg LH, Shaw CE, Powell JF, Al-Chalabi A (2017) ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging 51:178171–178179

doi: 10.1016/j.neurobiolaging.2016.11.010

Chio A, Calvo A, Moglia C, Canosa A, Brunetti M, Barberis M, Restagno G, Conte A, Bisogni G, Marangi G, Moncada A, Lattante S, Zollino M, Sabatelli M, Bagarotti A, Corrado L, Mora G, Bersano E, Mazzini L, D’Alfonso Parals S (2015) ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology 84:251–258

pubmed: 25527265 doi: 10.1212/WNL.0000000000001159

Scarlino S, Domi T, Pozzi L, Romano A, Pipitone GB, Falzone YM, Mosca L, Penco S, Lunetta C, Sansone V, Tremolizzo L, Fazio R, Agosta F, Filippi M, Carrera P, Riva N, Quattrini A (2020) Burden of Rare Variants in ALS and axonal hereditary neuropathy genes influence survival in ALS: insights from a next generation sequencing study of an Italian ALS Cohort. Int J Mol Sci. 21

Ghirelli A, Spinelli EG, Canu E, Domi T, Basaia S, Castelnovo V, Pozzi L, Magnani G, Caso F, Caroppo P, Prioni S, Villa C, Riva N, Quattrini A, Carrera P, Filippi M, Agosta F (2023) Case report: coexistence of C9orf72 expansion and progranulin mutation in a case of genetic frontotemporal dementia-clinical features and neuroimaging correlates. J Neurol 270:5102–5109

pubmed: 37382630 pmcid: 10511558 doi: 10.1007/s00415-023-11839-3

Moreira MC, Klur S, Watanabe M, Nemeth AH, Le Ber I, Moniz JC, Tranchant C, Aubourg P, Tazir M, Schols L, Pandolfo M, Schulz JB, Pouget J, Calvas P, Shizuka-Ikeda M, Shoji M, Tanaka M, Izatt L, Shaw CE, M’Zahem A, Dunne E, Bomont P, Benhassine T, Bouslam N, Stevanin G, Brice A, Guimaraes J, Mendonca P, Barbot C, Coutinho P, Sequeiros J, Durr A, Warter JM, Koenig M (2004) Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 36:225–227

pubmed: 14770181 doi: 10.1038/ng1303

Bennett CL, Dastidar S, Arnold FJ, McKinstry SU, Stockford C, Freibaum BD, Sopher BL, Wu M, Seidner G, Joiner W, Taylor JP, West RJH, La Spada AR (2023) Senataxin helicase, the causal gene defect in ALS4, is a significant modifier of C9orf72 ALS G4C2 and arginine-containing dipeptide repeat toxicity. Acta Neuropathol Commun 11:164

pubmed: 37845749 pmcid: 10580588 doi: 10.1186/s40478-023-01665-z

Pupillo E, Messina P, Giussani G, Logroscino G, Zoccolella S, Chio A, Calvo A, Corbo M, Lunetta C, Marin B, Mitchell D, Hardiman O, Rooney J, Stevic Z, Bandettini di Poggio M, Filosto M, Cotelli MS, Perini M, Riva N, Tremolizzo L, Vitelli E, Damiani D, Beghi E, Consortium E (2014) Physical activity and amyotrophic lateral sclerosis: a European population-based case-control study. Ann Neurol 75:708–716

pubmed: 24706338 doi: 10.1002/ana.24150

D’Ovidio F, Rooney JPK, Visser AE, Manera U, Beghi E, Logroscino G, Vermeulen RCH, Veldink JH, van den Berg LH, Hardiman O, Chio A, Mc E (2019) Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. J Neurol Neurosurg Psychiatry 90:11–19

pubmed: 30076269 doi: 10.1136/jnnp-2018-318559

Visser AE, Rooney JPK, D’Ovidio F, Westeneng HJ, Vermeulen RCH, Beghi E, Chio A, Logroscino G, Hardiman O, Veldink JH, van den Berg LH, Mc E (2018) Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 89:797–803

pubmed: 29685899 doi: 10.1136/jnnp-2017-317724

Pupillo E, Messina P, Logroscino G, Zoccolella S, Chio A, Calvo A, Corbo M, Lunetta C, Micheli A, Millul A, Vitelli E, Beghi E, Consortium E (2012) Trauma and amyotrophic lateral sclerosis: a case-control study from a population-based registry. Eur J Neurol Off J Eur Fed Neurol Soc 19:1509–1517

Pupillo E, Poloni M, Bianchi E, Giussani G, Logroscino G, Zoccolella S, Chio A, Calvo A, Corbo M, Lunetta C, Marin B, Mitchell D, Hardiman O, Rooney J, Stevic Z, Bandettini di Poggio M, Filosto M, Cotelli MS, Perini M, Riva N, Tremolizzo L, Vitelli E, Damiani D, Beghi E, Consortiumdagger E (2018) Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. Amyotrophic Lateral Sclerosis Frontotemporal Degener 19:118–125

doi: 10.1080/21678421.2017.1386687

Ingre C, Roos PM, Piehl F, Kamel F, Fang F (2015) Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol 7:181–193

pubmed: 25709501 pmcid: 4334292

Hamidou B, Couratier P, Besançon C, Nicol M, Preux PM, Marin B (2014) Epidemiological evidence that physical activity is not a risk factor for ALS. Eur J Epidemiol 29:459–475

pubmed: 24986107 doi: 10.1007/s10654-014-9923-2

Zhu Q, Zhou J, Zhang Y, Huang H, Han J, Cao B, Xu D, Zhao Y, Chen G (2023) Risk factors associated with amyotrophic lateral sclerosis based on the observational study: a systematic review and meta-analysis. Front Neurosci 17:1196722

pubmed: 37284659 pmcid: 10239956 doi: 10.3389/fnins.2023.1196722

Åberg M, Nyberg J, Robertson J, Kuhn G, Schiöler L, Nissbrandt H, Waern M, Torén K (2018) Risk factors in Swedish young men for amyotrophic lateral sclerosis in adulthood. J Neurol 265:460–470

pubmed: 29285652 doi: 10.1007/s00415-017-8719-1

Russell ER, Mackay DF, Stewart K, MacLean JA, Pell JP, Stewart W (2021) Association of field position and career length with risk of neurodegenerative disease in male former professional soccer players. JAMA Neurol 78:1057–1063

pubmed: 34338724 doi: 10.1001/jamaneurol.2021.2403

Chio A, Calvo A, Dossena M, Ghiglione P, Mutani R, Mora G (2009) ALS in Italian professional soccer players: the risk is still present and could be soccer-specific. Amyotrophic Lateral Sclerosis Off Publ World Fed Neurol Res Group Motor Neuron Dis 10:205–209

M H, Np R, (2020) Physical activity as a risk factor for amyotrophic lateral sclerosis-findings from three large European cohorts. J Neurol 267:2173–2175

pubmed: 32577865 doi: 10.1007/s00415-020-09995-x

Zheng X, Wang S, Huang J, Lin J, Yang T, Xiao Y, Jiang Q, Huang R, Li C, Shang H (2023) Physical activity as risk factor in amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol 270:2438–2450

pubmed: 36670248 doi: 10.1007/s00415-022-11555-4

Diekmann K, Kuzma-Kozakiewicz M, Piotrkiewicz M, Gromicho M, Grosskreutz J, Andersen PM, Carvalho M, Uysal H, Osmanovic A, Schreiber-Katz O, Petri S, Körner S (2020) Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J Neurol 267:2130–2141

pubmed: 32266542 doi: 10.1007/s00415-020-09799-z

Chapman L, Cooper-Knock J, Shaw PJ (2023) Physical activity as an exogenous risk factor for amyotrophic lateral sclerosis: a review of the evidence. Brain J Neurol 146:1745–1757

doi: 10.1093/brain/awac470

Julian TH, Glascow N, Barry ADF, Moll T, Harvey C, Klimentidis YC, Newell M, Zhang S, Snyder MP, Cooper-Knock J, Shaw PJ (2021) Physical exercise is a risk factor for amyotrophic lateral sclerosis: convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine 68:103397

pubmed: 34051439 pmcid: 8170114 doi: 10.1016/j.ebiom.2021.103397

Westeneng H-J, Veenhuijzen K, Spek RA, Peters S, Visser AE, Rheenen W, Veldink JH, Berg LH (2021) Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study. Lancet Neurol 20:373–384

pubmed: 33894192 doi: 10.1016/S1474-4422(21)00042-9

Vasta R, Callegaro S, Sgambetterra S, Cabras S, Di Pede F, De Mattei F, Matteoni E, Grassano M, Bombaci A, De Marco G, Fuda G, Marchese G, Palumbo F, Canosa A, Mazzini L, De Marchi F, Moglia C, Manera U, Chiò A, Calvo A (2023) Presymptomatic geographical distribution of ALS patients suggests the involvement of environmental factors in the disease pathogenesis. J Neurol 270:5475–5482

pubmed: 37491680 pmcid: 10576667 doi: 10.1007/s00415-023-11888-8

Wändell P, Fredrikson S, Carlsson AC, Li X, Sundquist J, Sundquist K (2022) Amyotrophic lateral sclerosis (ALS) among immigrant groups and Swedish-born individuals: a cohort study of all adults 18 years of age and older in Sweden. J Neurol 269:1989–1995

pubmed: 34427755 doi: 10.1007/s00415-021-10765-6

Sagiraju HKR, Živković S, VanCott AC, Patwa H, Ruiz G, de Porras D, Amuan ME, Pugh MJV (2020) Amyotrophic lateral sclerosis among veterans deployed in support of post-9/11 U.S. Confl Mil Med 185:e501–e509

doi: 10.1093/milmed/usz350

Re DB, Yan B, Calderón-Garcidueñas L, Andrew AS, Tischbein M, Stommel EW (2022) A perspective on persistent toxicants in veterans and amyotrophic lateral sclerosis: identifying exposures determining higher ALS risk. J Neurol 269:2359–2377

pubmed: 34973105 pmcid: 9021134 doi: 10.1007/s00415-021-10928-5

Goutman SA, Boss J, Jang D-G, Mukherjee B, Richardson RJ, Batterman S, Feldman EL (2023) Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort. J Neurol Neurosurg Psychiatry:jnnp-2023–332121

Gresham LS, Molgaard CA, Golbeck AL, Smith R (1986) Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology 5:29–38

pubmed: 3748267 doi: 10.1159/000110810

Kamalian A, Foroughmand I, Koski L, Darvish M, Saghazadeh A, Kamalian A, Razavi SZE, Abdi S, Dehgolan SR, Fotouhi A, Roos PM (2023) Metal concentrations in cerebrospinal fluid, blood, serum, plasma, hair, and nails in amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Trace Elem Med Biol 78:127165

pubmed: 37018859 doi: 10.1016/j.jtemb.2023.127165

Ravits J (2014) Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Exper Neurol 262 Pt B:121–126

Bendotti C, Bonetto V, Pupillo E, Logroscino G, Al-Chalabi A, Lunetta C, Riva N, Mora G, Lauria G, Weishaupt JH, Agosta F, Malaspina A, Basso M, Greensmith L, Van Den Bosch L, Ratti A, Corbo M, Hardiman O, Chio A, Silani V, Beghi E (2020) Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Frontotemporal Degener 21:485–495

doi: 10.1080/21678421.2020.1779298

Chio A, Calvo A, Moglia C, Mazzini L, Mora G, group Ps (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82:740–746

pubmed: 21402743 doi: 10.1136/jnnp.2010.235952

Al-Chalabi A, Hardiman O, Kiernan MC, Chio A, Rix-Brooks B, van den Berg LH (2016) Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 15:1182–1194

pubmed: 27647646 doi: 10.1016/S1474-4422(16)30199-5

Schabhuttl M, Wieland T, Senderek J, Baets J, Timmerman V, De Jonghe P, Reilly MM, Stieglbauer K, Laich E, Windhager R, Erwa W, Trajanoski S, Strom TM, Auer-Grumbach M (2014) Whole-exome sequencing in patients with inherited neuropathies: outcome and challenges. J Neurol 261:970–982

pubmed: 24627108 doi: 10.1007/s00415-014-7289-8

Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, Prudlo J, Peraus G, Hanemann CO, Stumm G, Ludolph AC (2004) Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 63:724–726

pubmed: 15326253 doi: 10.1212/01.WNL.0000134608.83927.B1

Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH (2003) Mutant dynactin in motor neuron disease. Nat Genet 33:455–456

pubmed: 12627231 doi: 10.1038/ng1123

Sevilla T, Cuesta A, Chumillas MJ, Mayordomo F, Pedrola L, Palau F, Vilchez JJ (2003) Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth neuropathy with vocal cord palsy and mutations in the GDAP1 gene. Brain J Neurol 126:2023–2033

doi: 10.1093/brain/awg202

Zimon M, Baets J, Fabrizi GM, Jaakkola E, Kabzinska D, Pilch J, Schindler AB, Cornblath DR, Fischbeck KH, Auer-Grumbach M, Guelly C, Huber N, De Vriendt E, Timmerman V, Suter U, Hausmanowa-Petrusewicz I, Niemann A, Kochanski A, De Jonghe P, Jordanova A (2011) Dominant GDAP1 mutations cause predominantly mild CMT phenotypes. Neurology 77:540–548

pubmed: 21753178 doi: 10.1212/WNL.0b013e318228fc70

Strickland AV, Schabhuttl M, Offenbacher H, Synofzik M, Hauser NS, Brunner-Krainz M, Gruber-Sedlmayr U, Moore SA, Windhager R, Bender B, Harms M, Klebe S, Young P, Kennerson M, Garcia AS, Gonzalez MA, Zuchner S, Schule R, Shy ME, Auer-Grumbach M (2015) Mutation screen reveals novel variants and expands the phenotypes associated with DYNC1H1. J Neurol. https://doi.org/10.1007/s00415-015-7727-2

doi: 10.1007/s00415-015-7727-2 pubmed: 26100331 pmcid: 4573829

Weedon MN, Hastings R, Caswell R, Xie W, Paszkiewicz K, Antoniadi T, Williams M, King C, Greenhalgh L, Newbury-Ecob R, Ellard S (2011) Exome sequencing identifies a DYNC1H1 mutation in a large pedigree with dominant axonal charcot-marie-tooth disease. Am J Hum Genet 89:308–312

pubmed: 21820100 pmcid: 3155164 doi: 10.1016/j.ajhg.2011.07.002

Liu YT, Laura M, Hersheson J, Horga A, Jaunmuktane Z, Brandner S, Pittman A, Hughes D, Polke JM, Sweeney MG, Proukakis C, Janssen JC, Auer-Grumbach M, Zuchner S, Shields KG, Reilly MM, Houlden H (2014) Extended phenotypic spectrum of KIF5A mutations: from spastic paraplegia to axonal neuropathy. Neurology 83:612–619

pubmed: 25008398 pmcid: 4141994 doi: 10.1212/WNL.0000000000000691

Daud D, Griffin H, Douroudis K, Kleinle S, Eglon G, Pyle A, Chinnery PF, Horvath R (2015) Whole exome sequencing and the clinician: we need clinical skills and functional validation in variant filtering. J Neurol 262:1673–1677

pubmed: 25957632 pmcid: 4503877 doi: 10.1007/s00415-015-7755-y

Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, Russ C, Shaw CE, Powell JF, Leigh PN (1999) Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 8:157–164

pubmed: 9931323 doi: 10.1093/hmg/8.2.157

Hensiek A, Kirker S, Reid E (2015) Diagnosis, investigation and management of hereditary spastic paraplegias in the era of next-generation sequencing. J Neurol 262:1601–1612

pubmed: 25480570 doi: 10.1007/s00415-014-7598-y

Gentile F, Scarlino S, Falzone YM, Lunetta C, Tremolizzo L, Quattrini A, Riva N (2019) The peripheral nervous system in amyotrophic lateral sclerosis: opportunities for translational research. Front Neurosci 13:601

pubmed: 31293369 pmcid: 6603245 doi: 10.3389/fnins.2019.00601

Scarlino S, Domi T, Pozzi L, Romano A, Pipitone GB, Falzone YM, Mosca L, Penco S, Lunetta C, Sansone V, Tremolizzo L, Fazio R, Agosta F, Filippi M, Carrera P, Riva N, Quattrini A (2020) Burden of rare variants in ALS and axonal hereditary neuropathy genes influence survival in ALS: insights from a next generation sequencing study of an Italian ALS cohort. Int J Mol Sci 21:3346

pubmed: 32397312 pmcid: 7246633 doi: 10.3390/ijms21093346

Previtali SC, Zhao E, Lazarevic D, Pipitone GB, Fabrizi GM, Manganelli F, Mazzeo A, Pareyson D, Schenone A, Taroni F, Vita G, Bellone E, Ferrarini M, Garibaldi M, Magri S, Padua L, Pennisi E, Pisciotta C, Riva N, Scaioli V, Scarlato M, Tozza S, Geroldi A, Jordanova A, Ferrari M, Molineris I, Reilly MM, Comi G, Carrera P, Devoto M, Bolino A (2019) Expanding the spectrum of genes responsible for hereditary motor neuropathies. J Neurol Neurosurg Psychiatry 90:1171–1179

pubmed: 31167812 doi: 10.1136/jnnp-2019-320717

Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, Al-Chalabi A (2018) Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 17:416–422

pubmed: 29525492 pmcid: 5899963 doi: 10.1016/S1474-4422(18)30054-1

Shellikeri S, Karthikeyan V, Martino R, Black SE, Zinman L, Keith J, Yunusova Y (2017) The neuropathological signature of bulbar-onset ALS: a systematic review. Neurosci Biobehav Rev 75:378–392

pubmed: 28163193 pmcid: 5425954 doi: 10.1016/j.neubiorev.2017.01.045

Shellikeri S, Keith J, Black SE, Zinman L, Yunusova Y (2020) Neuropathology of speech network distinguishes bulbar from nonbulbar amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 79:284–295

pubmed: 31951003 doi: 10.1093/jnen/nlz130

Mitsumoto H, Del Bene M (2000) Improving the quality of life for people with ALS: the challenge ahead. Amyotrophic Lateral Sclerosis Other Motor Neuron Disord Off Publ World Fed Neurol Res Group Motor Neur Dis 1:329–336

Goldstein LH, Atkins L, Leigh PN (2002) Correlates of Quality of Life in people with motor neuron disease (MND). Amyotrophic Lateral Sclerosis Other Motor Neuron Disord Off Publ World Fed Neurol Res Group Motor Neur Dis 3:123–129

Saleem F, Munakomi S (2024) Pseudobulbar Palsy. In: StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Sunil Munakomi declares no relevant financial relationships with ineligible companies.

Goutman SA, Hardiman O, Al-Chalabi A, Chio A, Savelieff MG, Kiernan MC, Feldman EL (2022) Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol 21:480–493

pubmed: 35334233 pmcid: 9513753 doi: 10.1016/S1474-4422(21)00465-8

Finegan E, Chipika RH, Li Hi Shing S, Hardiman O, Bede P (2019) Pathological crying and laughing in motor neuron disease: pathobiology, screening. Interven Front Neurol 10:260

doi: 10.3389/fneur.2019.00260

Karam C, Scelsa SN, Macgowan DJ (2010) The clinical course of progressive bulbar palsy. Amyotrophic Lateral Sclerosis Off Publ World Fed Neurol Res Group Motor Neur Dis 11:364–368

Gaig C, Graus F, Compta Y, Hogl B, Bataller L, Bruggemann N, Giordana C, Heidbreder A, Kotschet K, Lewerenz J, Macher S, Marti MJ, Montojo T, Perez-Perez J, Puertas I, Seitz C, Simabukuro M, Tellez N, Wandinger KP, Iranzo A, Ercilla G, Sabater L, Santamaria J, Dalmau J (2017) Clinical manifestations of the anti-IgLON5 disease. Neurology 88:1736–1743

pubmed: 28381508 pmcid: 5409845 doi: 10.1212/WNL.0000000000003887

Sista SR, Crum B, Aboseif A, Devine MF, Zekeridou A, Hammami MB, Rezk MM, Truffert A, Lalive PH, Kunchok A, McKeon A, Dubey D (2022) Motor-neuron-disease-like phenotype associated with IgLON5 disease. J Neurol 269:6139–6144

pubmed: 35857139 pmcid: 9578379 doi: 10.1007/s00415-022-11262-0

Origone P, Caponnetto C, Mantero V, Cichero E, Fossa P, Geroldi A, Verdiani S, Bellone E, Mancardi G, Mandich P (2012) Fast course ALS presenting with vocal cord paralysis: clinical features, bioinformatic and modelling analysis of the novel SOD1 Gly147Ser mutation. Amyotrophic Lateral Sclerosis Off Publ World Fed Neurol Res Group Motor Neuron Dis 13:144–148

Capece G, Ceroni M, Alfonsi E, Palmieri I, Cereda C, Diamanti L (2021) Case Report: Laryngospasm as Initial Manifestation of Amyotrophic Lateral Sclerosis in a Long-Survival Patient With Heterozygous p.D90A - SOD1 Mutation. Front Neurol 12:708885

pubmed: 34659083 pmcid: 8514733 doi: 10.3389/fneur.2021.708885

Dalla Bella E, Rigamonti A, Mantero V, Morbin M, Saccucci S, Gellera C, Mora G, Lauria G (2014) Heterozygous D90A-SOD1 mutation in a patient with facial onset sensory motor neuronopathy (FOSMN) syndrome: a bridge to amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 85:1009–1011

pubmed: 24591457 doi: 10.1136/jnnp-2013-307416

de Boer EMJ, Barritt AW, Elamin M, Anderson SJ, Broad R, Nisbet A, Goedee HS, Vazquez Costa JF, Prudlo J, Vedeler CA, Fernandez JP, Panades MP, Alberti Aguilo MA, Bella ED, Lauria G, Pinto W, de Souza PVS, Oliveira ASB, Toro C, van Iersel J, Parson M, Harschnitz O, van den Berg LH, Veldink JH, Al-Chalabi A, Leigh PN, van Es MA (2021) Facial onset sensory and motor neuronopathy: new cases, cognitive changes, and pathophysiology. Neurol Clin Pract 11:147–157

pubmed: 33842068 pmcid: 8032419 doi: 10.1212/CPJ.0000000000000834

Pinto S, Gromicho M, Oliveira Santos MO, Swash M, De Carvalho M (2023) Respiratory onset in amyotrophic lateral sclerosis: clinical features and spreading pattern. Amyotrophic Lateral Sclerosis Frontotemporal Degener 24:40–44

doi: 10.1080/21678421.2022.2067777

Shoesmith CL, Findlater K, Rowe A, Strong MJ (2007) Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 78:629–631

pubmed: 17088331 doi: 10.1136/jnnp.2006.103564

Agarwal S, Highton-Williamson E, Caga J, Matamala JM, Dharmadasa T, Howells J, Zoing MC, Shibuya K, Geevasinga N, Vucic S, Hodges JR, Ahmed RM, Kiernan MC (2018) Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum. J Neurol 265:1819–1828

pubmed: 29868980 doi: 10.1007/s00415-018-8917-5

Gazulla J, Ferrer I, Izquierdo-Alvarez S, Alvarez S, Sanchez-Alcudia R, Bestue-Cardiel M, Seral M, Benavente I, Sierra-Martinez E, Berciano J (2019) Hereditary primary lateral sclerosis and progressive nonfluent aphasia. J Neurol 266:1079–1090

pubmed: 30834979 doi: 10.1007/s00415-019-09235-x

Finegan E, Chipika RH, Li Hi Shing S, Doherty MA, Hengeveld JC, Vajda A, Donaghy C, McLaughlin RL, Pender N, Hardiman O, Bede P (2019) The clinical and radiological profile of primary lateral sclerosis: a population-based study. J Neurol 266:2718–2733

pubmed: 31325016 doi: 10.1007/s00415-019-09473-z

Canu E, Agosta F, Galantucci S, Chio A, Riva N, Silani V, Falini A, Comi G, Filippi M (2013) Extramotor damage is associated with cognition in primary lateral sclerosis patients. PLoS ONE 8:e82017

pubmed: 24349172 pmcid: 3857796 doi: 10.1371/journal.pone.0082017

Kleinerova J, Tahedl M, Tan EL, Delaney S, Hengeveld JC, Doherty MA, McLaughlin RL, Hardiman O, Chang KM, Finegan E, Bede P (2024) Supra- and infra-tentorial degeneration patterns in primary lateral sclerosis: a multimodal longitudinal neuroradiology study. J Neurol

Rosenbohm A, Del Tredici K, Braak H, Huppertz HJ, Ludolph AC, Muller HP, Kassubek J (2022) Involvement of cortico-efferent tracts in flail arm syndrome: a tract-of-interest-based DTI study. J Neurol 269:2619–2626

pubmed: 34676447 doi: 10.1007/s00415-021-10854-6

Jaiser SR, Mitra D, Williams TL, Baker MR (2019) Mills’ syndrome revisited. J Neurol 266:667–679

pubmed: 30631918 pmcid: 6394692 doi: 10.1007/s00415-019-09186-3

Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobaGyi T, Rosenfeld J, Silani V, Ince PG, Turner MR (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis Frontotemporal Degener 18:153–174

doi: 10.1080/21678421.2016.1267768

Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, Colville S, Heverin M, Mays I, Pal S, Pender N, Pinto-Grau M, Radakovic R, Shaw CE, Stephenson L, Swingler R, Vajda A, Al-Chalabi A, Hardiman O, Abrahams S (2018) ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology 91:e1370–e1380

pubmed: 30209236 pmcid: 6177274 doi: 10.1212/WNL.0000000000006317

Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ (2016) The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry 87:611–619

pubmed: 26283685 doi: 10.1136/jnnp-2015-310734

Watanabe Y, Raaphorst J, Izumi Y, Yoshino H, Ito S, Adachi T, Takigawa H, Masuda M, Atsuta N, Adachi Y, Isose S, Arai K, Yokota O, Oda M, Ogino M, Ichikawa H, Hasegawa K, Kimura H, Shimizu T, Aiba I, Yabe H, Kanba M, Kusumi K, Aoki T, Hiroe Y, Watanabe H, Nishiyama K, Nomoto M, Sobue G, Beeldman E, Hanajima R, Nakashima K, group A-F-Q-Jr (2020) Cognitive and behavioral status in Japanese ALS patients: a multicenter study. J Neurol 267:1321–1330

pubmed: 31955246 doi: 10.1007/s00415-019-09655-9

Strong MJ (2017) Revisiting the concept of amyotrophic lateral sclerosis as a multisystems disorder of limited phenotypic expression. Curr Opin Neurol 30:599–607

pubmed: 28914734 doi: 10.1097/WCO.0000000000000488

Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, Lynch C, Pender N, Hardiman O (2012) The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 83:102–108

pubmed: 21836033 doi: 10.1136/jnnp-2011-300188

Vinceti G, Olney N, Mandelli ML, Spina S, Hubbard HI, Santos-Santos MA, Watson C, Miller ZA, Lomen-Hoerth C, Nichelli P, Miller BL, Grinberg LT, Seeley WW, Gorno-Tempini ML (2019) Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates. Amyotroph Lateral Scler Frontotemporal Degener 20:146–158

pubmed: 30668155 pmcid: 6759325 doi: 10.1080/21678421.2018.1556695

Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, Murphy J, Shoesmith C, Rosenfeld J, Leigh PN, Bruijn L, Ince P, Figlewicz D (2009) Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10:131–146

pubmed: 19462523 doi: 10.1080/17482960802654364

Consonni M, Catricalà E, Dalla Bella E, Gessa VC, Lauria G, Cappa SF (2016) Beyond the consensus criteria: multiple cognitive profiles in amyotrophic lateral sclerosis? Cortex 81:162–167

pubmed: 27236371 doi: 10.1016/j.cortex.2016.04.014

Maier PM, Iggena D, Meyer T, Finke C, Ploner CJ (2023) Memory-guided navigation in amyotrophic lateral sclerosis. J Neurol 270:4031–4040

pubmed: 37154895 pmcid: 10344997 doi: 10.1007/s00415-023-11753-8

Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477

pubmed: 21810890 pmcid: 3170532 doi: 10.1093/brain/awr179

Long Z, Irish M, Foxe D, Hodges JR, Piguet O, Burrell JR (2021) Heterogeneity of behavioural and language deficits in FTD-MND. J Neurol 268:2876–2889

pubmed: 33609157 doi: 10.1007/s00415-021-10451-7

Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, O’Brien C, Phukan J, Lynch C, Pender N, Hardiman O (2013) Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 80:1590–1597

pubmed: 23553481 doi: 10.1212/WNL.0b013e31828f18ac

Schrempf T, Finsel J, Uttner I, Ludolph AC, Lulé D (2022) Neuropsychological deficits have only limited impact on psychological well-being in amyotrophic lateral sclerosis. J Neurol 269:1369–1374

pubmed: 34215919 doi: 10.1007/s00415-021-10690-8

Spataro R, La Bella V (2021) The capacity to consent to treatment in amyotrophic lateral sclerosis: a preliminary report. J Neurol 268:219–226

pubmed: 32766931 doi: 10.1007/s00415-020-10136-7

Burke T, Hardiman O, Pinto-Grau M, Lonergan K, Heverin M, Tobin K, Staines A, Galvin M, Pender N (2018) Longitudinal predictors of caregiver burden in amyotrophic lateral sclerosis: a population-based cohort of patient-caregiver dyads. J Neurol 265:793–808

pubmed: 29396678 doi: 10.1007/s00415-018-8770-6

Burke T, Elamin M, Galvin M, Hardiman O, Pender N (2015) Caregiver burden in amyotrophic lateral sclerosis: a cross-sectional investigation of predictors. J Neurol 262:1526–1532

pubmed: 25904206 doi: 10.1007/s00415-015-7746-z

Consonni M, Telesca A, Dalla Bella E, Bersano E, Lauria G (2020) Amyotrophic lateral sclerosis patients’ and caregivers’ distress and loneliness during COVID-19 lockdown. J Neurol. https://doi.org/10.1007/s00415-020-10080-6

doi: 10.1007/s00415-020-10080-6 pubmed: 32696342 pmcid: 7372539

Caga J, Hsieh S, Highton-Williamson E, Zoing MC, Ramsey E, Devenney E, Ahmed RM, Kiernan MC (2018) Apathy and its impact on patient outcome in amyotrophic lateral sclerosis. J Neurol 265:187–193

pubmed: 29189922 doi: 10.1007/s00415-017-8688-4

Frith CD, Frith U (2007) Social cognition in humans. Curr Biol 17:R724-732

pubmed: 17714666 doi: 10.1016/j.cub.2007.05.068

Arioli M, Crespi C, Canessa N (2018) Social cognition through the lens of cognitive and clinical neuroscience. Biomed Res Int 2018:4283427

pubmed: 30302338 pmcid: 6158937 doi: 10.1155/2018/4283427

Carelli L, Solca F, Tagini S, Torre S, Verde F, Ticozzi N, Consonni M, Ferrucci R, Pravettoni G, Poletti B, Silani V (2021) Emotional processing and experience in amyotrophic lateral sclerosis: a systematic and critical review. Brain Sci. https://doi.org/10.3390/brainsci11101356

doi: 10.3390/brainsci11101356 pubmed: 34679420 pmcid: 8534224

Bora E (2017) Meta-analysis of social cognition in amyotrophic lateral sclerosis. Cortex 88:1–7

pubmed: 28002755 doi: 10.1016/j.cortex.2016.11.012

Girardi A, MacPherson SE, Abrahams S (2011) Deficits in emotional and social cognition in amyotrophic lateral sclerosis. Neuropsychology 25:53–65

pubmed: 20919762 doi: 10.1037/a0020357

Crespi C, Cerami C, Dodich A, Canessa N, Arpone M, Iannaccone S, Corbo M, Lunetta C, Scola E, Falini A, Cappa SF (2014) Microstructural white matter correlates of emotion recognition impairment in Amyotrophic Lateral Sclerosis. Cortex 53:1–8

pubmed: 24534360 doi: 10.1016/j.cortex.2014.01.002

van der Hulst EJ, Bak TH, Abrahams S (2015) Impaired affective and cognitive theory of mind and behavioural change in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 86:1208–1215

pubmed: 25476003 doi: 10.1136/jnnp-2014-309290

Cerami C, Dodich A, Canessa N, Crespi C, Iannaccone S, Corbo M, Lunetta C, Consonni M, Scola E, Falini A, Cappa SF (2014) Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study. Amyotrophic Lateral Sclerosis Frontotemporal Degener 15:21–29

doi: 10.3109/21678421.2013.785568

Cavallo M, Adenzato M, Macpherson SE, Karwig G, Enrici I, Abrahams S (2011) Evidence of social understanding impairment in patients with amyotrophic lateral sclerosis. PLoS ONE 6:e25948

pubmed: 21998727 pmcid: 3187828 doi: 10.1371/journal.pone.0025948

Stern Y (2006) Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 20:S69-74

pubmed: 16917199 doi: 10.1097/00002093-200607001-00010

Stern Y (2009) Cognitive reserve. Neuropsychologia 47:2015–2028

pubmed: 19467352 pmcid: 2739591 doi: 10.1016/j.neuropsychologia.2009.03.004

Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, Belleville S, Cantilon M, Chetelat G, Ewers M, Franzmeier N, Kempermann G, Kremen WS, Okonkwo O, Scarmeas N, Soldan A, Udeh-Momoh C, Valenzuela M, Vemuri P, Vuoksimaa E, the Reserve RsaPFPEDaCFW (2020) Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement 16:1305–1311

pubmed: 30222945 doi: 10.1016/j.jalz.2018.07.219

Rhodes E, Alfa S, Jin HA, Massimo L, Elman L, Amado D, Baer M, Quinn C, McMillan CT (2024) Cognitive reserve in ALS: the role of occupational skills and requirements. Amyotrophic Lateral Sclerosis Frontotemporal Degener. https://doi.org/10.1080/21678421.2024.2336113

doi: 10.1080/21678421.2024.2336113

Canosa A, Palumbo F, Iazzolino B, Peotta L, Di Pede F, Manera U, Vasta R, Grassano M, Solero L, Arena V, Moglia C, Calvo A, Chiò A, Pagani M (2021) The interplay among education, brain metabolism, and cognitive impairment suggests a role of cognitive reserve in Amyotrophic Lateral Sclerosis. Neurobiol Aging 98:205–213

pubmed: 33316576 doi: 10.1016/j.neurobiolaging.2020.11.010

Temp AGM, Prudlo J, Vielhaber S, Machts J, Hermann A, Teipel SJ, Kasper E (2021) Cognitive reserve and regional brain volume in amyotrophic lateral sclerosis. Cortex 139:240–248

pubmed: 33892294 doi: 10.1016/j.cortex.2021.03.005

Consonni M, Dalla Bella E, Bersano E, Telesca A, Lauria G (2021) Cognitive reserve is associated with altered clinical expression in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Frontotemporal Degener 22:237–247

doi: 10.1080/21678421.2020.1849306

Costello E, Rooney J, Pinto-Grau M, Burke T, Elamin M, Bede P, McMackin R, Dukic S, Vajda A, Heverin M, Hardiman O, Pender N (2021) Cognitive reserve in amyotrophic lateral sclerosis (ALS): a population-based longitudinal study. J Neurol Neurosurg Psychiatry 92:460–465

pubmed: 33563807 doi: 10.1136/jnnp-2020-324992

Temp AGM, Kasper E, Machts J, Vielhaber S, Teipel S, Hermann A, Prudlo J (2022) Cognitive reserve protects ALS-typical cognitive domains: a longitudinal study. Ann Clin Transl Neurol 9:1212–1223

pubmed: 35866289 pmcid: 9380174 doi: 10.1002/acn3.51623

Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, McDermott MP, Shefner J, Stanislaw C, Abrahams S, Cosentino S, Andersen PM, Finkel RS, Granit V, Grignon AL, Rohrer JD, McMillan CT, Grossman M, Al-Chalabi A, Turner MR, Workshop FIP-SA (2022) Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain 145:27–44

pubmed: 34677606 doi: 10.1093/brain/awab404

Behler A, Knehr A, Finsel J, Kunz MS, Lang C, Müller K, Müller HP, Pinkhardt EH, Ludolph AC, Lulé D, Kassubek J (2021) Eye movement alterations in presymptomatic C9orf72 expansion gene carriers. J Neurol 268:3390–3399

pubmed: 33709219 pmcid: 8357645 doi: 10.1007/s00415-021-10510-z

Lulé DE, Müller HP, Finsel J, Weydt P, Knehr A, Winroth I, Andersen P, Weishaupt J, Uttner I, Kassubek J, Ludolph AC (2020) Deficits in verbal fluency in presymptomatic. J Neurol Neurosurg Psychiatry 91:1195–1200

pubmed: 32855285 doi: 10.1136/jnnp-2020-323671

Chiò A, Moglia C, Canosa A, Manera U, Vasta R, Brunetti M, Barberis M, Corrado L, D'Alfonso S, Bersano E, Sarnelli MF, Solara V, Zucchetti JP, Peotta L, Iazzolino B, Mazzini L, Mora G, Calvo A (2019) Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology

Iazzolino B, Peotta L, Zucchetti JP, Canosa A, Manera U, Vasta R, Grassano M, Palumbo F, Brunetti M, Barberis M, Sbaiz L, Moglia C, Calvo A, Chiò A (2021) Differential neuropsychological profile of patients with amyotrophic lateral sclerosis with and without. Neurology 96:e141–e152

pubmed: 33106391 doi: 10.1212/WNL.0000000000011093

Canosa A, Pagani M, Brunetti M, Barberis M, Iazzolino B, Ilardi A, Cammarosano S, Manera U, Moglia C, Calvo A, Cistaro A, Chiò A (2019) Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis. Eur J Neurol 26:306–312

pubmed: 30240096 doi: 10.1111/ene.13812

Piao YS, Wakabayashi K, Kakita A, Yamada M, Hayashi S, Morita T, Ikuta F, Oyanagi K, Takahashi H (2003) Neuropathology with clinical correlations of sporadic amyotrophic lateral sclerosis: 102 autopsy cases examined between 1962 and 2000. Brain Pathol 13:10–22

pubmed: 12580541 doi: 10.1111/j.1750-3639.2003.tb00002.x

Cividini C, Basaia S, Spinelli EG, Canu E, Castelnovo V, Riva N, Cecchetti G, Caso F, Magnani G, Falini A, Filippi M, Agosta F (2022) Amyotrophic lateral sclerosis-frontotemporal dementia: shared and divergent neural correlates across the clinical spectrum. Neurology 98:e402–e415

pubmed: 34853179 pmcid: 8793105 doi: 10.1212/WNL.0000000000013123

Consonni M, Contarino VE, Catricalà E, Dalla Bella E, Pensato V, Gellera C, Lauria G, Cappa SF (2018) Cortical markers of cognitive syndromes in amyotrophic lateral sclerosis. Neuroimage Clin 19:675–682

pubmed: 30023173 pmcid: 6046611 doi: 10.1016/j.nicl.2018.05.020

Consonni M, Cappa SF, Dalla Bella E, Contarino VE, Lauria G (2019) Cortical correlates of behavioural change in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 90:380–386

pubmed: 30322899 doi: 10.1136/jnnp-2018-318619

Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K (2013) Amyotrophic lateral sclerosis–a model of corticofugal axonal spread. Nat Rev Neurol 9:708–714

pubmed: 24217521 pmcid: 3943211 doi: 10.1038/nrneurol.2013.221

Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM, Wood EM, Baek Y, Kwong L, Lee EB, Elman L, McCluskey L, Fang L, Feldengut S, Ludolph AC, Lee VM, Braak H, Trojanowski JQ (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74:20–38

pubmed: 23686809 pmcid: 3785076 doi: 10.1002/ana.23937

Castelnovo V, Canu E, Calderaro D, Riva N, Poletti B, Basaia S, Solca F, Silani V, Filippi M, Agosta F (2020) Progression of brain functional connectivity and frontal cognitive dysfunction in ALS. NeuroImage Clinical 28:102509

pubmed: 33395998 pmcid: 7708866 doi: 10.1016/j.nicl.2020.102509

Spinelli EG, Ghirelli A, Riva N, Canu E, Castelnovo V, Domi T, Pozzi L, Carrera P, Silani V, Chio A, Filippi M, Agosta F (2022) Profiling morphologic MRI features of motor neuron disease caused by TARDBP mutations. Front Neurol 13:931006

pubmed: 35911889 pmcid: 9334911 doi: 10.3389/fneur.2022.931006

Lulé D, Böhm S, Müller HP, Aho-Özhan H, Keller J, Gorges M, Loose M, Weishaupt JH, Uttner I, Pinkhardt E, Kassubek J, Del Tredici K, Braak H, Abrahams S, Ludolph AC (2018) Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosis. Cortex 101:163–171

pubmed: 29477906 doi: 10.1016/j.cortex.2018.01.004

Consonni M, Dalla Bella E, Contarino VE, Bersano E, Lauria G (2020) Cortical thinning trajectories across disease stages and cognitive impairment in amyotrophic lateral sclerosis. Cortex

Takeda T, Kokubun S, Saito Y, Tsuneyama A, Ishikawa A, Isose S, Ito K, Arai K, Koreki A, Sugiyama A, Kuwabara S, Honda K (2022) Progressive medial temporal degeneration with TDP-43 pathology is associated with upper limb and bulbar onset types of amyotrophic lateral sclerosis. J Neurol 269:5497–5509

pubmed: 35708789 doi: 10.1007/s00415-022-11217-5

McHutchison CA, Leighton DJ, McIntosh A, Cleary E, Warner J, Porteous M, Chandran S, Pal S, Abrahams S (2020) Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND. J Neurol Neurosurg Psychiatry 91:245–253

pubmed: 31871139 doi: 10.1136/jnnp-2019-321737

Mioshi E, Caga J, Lillo P, Hsieh S, Ramsey E, Devenney E, Hornberger M, Hodges JR, Kiernan MC (2014) Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology 82:149–155

pubmed: 24336140 doi: 10.1212/WNL.0000000000000023

Zucchi E, Ticozzi N, Mandrioli J (2019) Psychiatric symptoms in amyotrophic lateral sclerosis: beyond a motor neuron disorder. Front Neurosci 13:175

pubmed: 30914912 pmcid: 6421303 doi: 10.3389/fnins.2019.00175

Carvalho TL, de Almeida LM, Lorega CM, Barata MF, Ferreira ML, de Brito-Marques PR, CaC C (2016) Depression and anxiety in individuals with amyotrophic lateral sclerosis: a systematic review. Trends Psychiatry Psychother 38:1–5

pubmed: 27007942 doi: 10.1590/2237-6089-2015-0030

Devenney EM, Tu S, Caga J, Ahmed RM, Ramsey E, Zoing M, Kwok J, Halliday GM, Piguet O, Hodges JR, Kiernan MC (2021) Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALS-FTD spectrum. Ann Clin Transl Neurol 8:1576–1591

pubmed: 34156763 pmcid: 8351398 doi: 10.1002/acn3.51363

Abrahams S, Newton J, Niven E, Foley J, Bak TH (2014) Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15:9–14

pubmed: 23781974 doi: 10.3109/21678421.2013.805784

Greco LC, Lizio A, Casiraghi J, Sansone VA, Tremolizzo L, Riva N, Solca F, Torre S, Ticozzi N, Filippi M, Silani V, Poletti B, Lunetta C (2022) A preliminary comparison between ECAS and ALS-CBS in classifying cognitive-behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patients. J Neurol 269:1899–1904

pubmed: 34410493 doi: 10.1007/s00415-021-10753-w

Beeldman E, Govaarts R, de Visser M, van Es MA, Pijnenburg YAL, Schmand BA, Raaphorst J (2021) Screening for cognition in amyotrophic lateral sclerosis: test characteristics of a new screen. J Neurol 268:2533–2540

pubmed: 33547953 pmcid: 8217007 doi: 10.1007/s00415-021-10423-x

Beswick E, Forbes D, Hassan Z, Wong C, Newton J, Carson A, Abrahams S, Chandran S, Pal S (2022) A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis. J Neurol 269:411–426

pubmed: 34120226 doi: 10.1007/s00415-021-10651-1

Beswick E, Park E, Wong C, Mehta AR, Dakin R, Chandran S, Newton J, Carson A, Abrahams S, Pal S (2021) A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis. J Neurol 268:4510–4521

pubmed: 32910255 doi: 10.1007/s00415-020-10203-z

Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133

pubmed: 17023659 doi: 10.1126/science.1134108

Ferrari G, Grisan E, Scarpa F, Fazio R, Comola M, Quattrini A, Comi G, Rama P, Riva N (2014) Corneal confocal microscopy reveals trigeminal small sensory fiber neuropathy in amyotrophic lateral sclerosis. Front Aging Neurosci 6:278

pubmed: 25360111 pmcid: 4199282 doi: 10.3389/fnagi.2014.00278

Calvo A, Chiò A, Pagani M, Cammarosano S, Dematteis F, Moglia C, Solero L, Manera U, Martone T, Brunetti M, Balma M, Castellano G, Barberis M, Cistaro A, Artusi CA, Vasta R, Montanaro E, Romagnolo A, Iazzolino B, Canosa A, Carrara G, Valentini C, Li T-Q, Nobili F, Lopiano L, Rizzone MG (2019) Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. J Neurol 266:1633–1642

pubmed: 30949819 doi: 10.1007/s00415-019-09305-0

Pupillo E, Bianchi E, Messina P, Chiveri L, Lunetta C, Corbo M, Filosto M, Lorusso L, Marin B, Mandrioli J, Riva N, Sasanelli F, Tremolizzo L, Beghi E, Eurals C (2015) Extrapyramidal and cognitive signs in amyotrophic lateral sclerosis: a population based cross-sectional study. Amyotrophic Lateral Sclerosis Frontotemporal Degener 16:324–330

doi: 10.3109/21678421.2015.1040028

Feron M, Couillandre A, Mseddi E, Termoz N, Abidi M, Bardinet E, Delgadillo D, Lenglet T, Querin G, Welter M-L, Le Forestier N, Salachas F, Bruneteau G, Del Mar AM, Debs R, Lacomblez L, Meininger V, Pélégrini-Issac M, Bede P, Pradat P-F, Marco G (2018) Extrapyramidal deficits in ALS: a combined biomechanical and neuroimaging study. J Neurol 265:2125–2136

pubmed: 29995291 doi: 10.1007/s00415-018-8964-y

Schönecker S, Hell F, Bötzel K, Wlasich E, Ackl N, Süßmair C, German FC, Otto M, Anderl-Straub S, Ludolph A, Kassubek J, Huppertz H-J, Diehl-Schmid J, Riedl L, Roßmeier C, Fassbender K, Lyros E, Kornhuber J, Oberstein TJ, Fliessbach K, Schneider A, Schroeter ML, Prudlo J, Lauer M, Jahn H, Levin J, Danek A (2019) The applause sign in frontotemporal lobar degeneration and related conditions. J Neurol 266:330–338

pubmed: 30506397 doi: 10.1007/s00415-018-9134-y

Bede P, Murad A, Lope J, Hardiman O, Chang KM (2022) Clusters of anatomical disease-burden patterns in ALS: a data-driven approach confirms radiological subtypes. J Neurol 269:4404–4413

pubmed: 35333981 pmcid: 9294023 doi: 10.1007/s00415-022-11081-3

Westeneng HJ, Walhout R, Straathof M, Schmidt R, Hendrikse J, Veldink JH, van den Heuvel MP, van den Berg LH (2016) Widespread structural brain involvement in ALS is not limited to the C9orf72 repeat expansion. J Neurol Neurosurg Psychiatry 87:1354–1360

pubmed: 27756805 doi: 10.1136/jnnp-2016-313959

Spinelli EG, Ghirelli A, Basaia S, Cividini C, Riva N, Canu E, Castelnovo V, Domi T, Magnani G, Caso F, Caroppo P, Prioni S, Rossi G, Tremolizzo L, Appollonio I, Silani V, Carrera P, Filippi M, Agosta F (2021) Structural MRI signatures in genetic presentations of the frontotemporal dementia/motor neuron disease spectrum. Neurology 97:e1594–e1607

pubmed: 34544819 pmcid: 8548958 doi: 10.1212/WNL.0000000000012702

Bede P, Chipika RH, Christidi F, Hengeveld JC, Karavasilis E, Argyropoulos GD, Lope J, Li Hi Shing S, Velonakis G, Dupuis L, Doherty MA, Vajda A, McLaughlin RL, Hardiman O (2021) Genotype-associated cerebellar profiles in ALS: focal cerebellar pathology and cerebro-cerebellar connectivity alterations. J Neurol Neurosurg Psychiatry 92:1197–1205

pubmed: 34168085 doi: 10.1136/jnnp-2021-326854

Finegan E, Siah WF, Li Hi Shing S, Chipika RH, Hardiman O, Bede P (2022) Cerebellar degeneration in primary lateral sclerosis: an under-recognized facet of PLS. Amyotrophic Lateral Sclerosis Frontotemporal Degener 23:542–553

doi: 10.1080/21678421.2021.2023188

Rohani M, Meysamie A, Zamani B, Sowlat MM, Akhoundi FH (2018) Reduced retinal nerve fiber layer (RNFL) thickness in ALS patients: a window to disease progression. J Neurol 265:1557–1562

pubmed: 29713825 doi: 10.1007/s00415-018-8863-2

Miscioscia A, Puthenparampil M, Blasi L, Rinaldi F, Perini P, Sorarù G, Gallo P (2023) Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy’s disease. J Neurol 270:4478–4486

pubmed: 37289322 pmcid: 10421755 doi: 10.1007/s00415-023-11802-2

Cerveró A, Casado A, Riancho J (2021) Retinal changes in amyotrophic lateral sclerosis: looking at the disease through a new window. J Neurol 268:2083–2089

pubmed: 31792674 doi: 10.1007/s00415-019-09654-w

Abdelhak A, Hübers A, Böhm K, Ludolph AC, Kassubek J, Pinkhardt EH (2018) In vivo assessment of retinal vessel pathology in amyotrophic lateral sclerosis. J Neurol 265:949–953

pubmed: 29464376 doi: 10.1007/s00415-018-8787-x

Ren Y, Liu W, Li Y, Sun B, Li Y, Yang F, Wang H, Li M, Cui F, Huang X (2018) Cutaneous somatic and autonomic nerve TDP-43 deposition in amyotrophic lateral sclerosis. J Neurol 265:1753–1763

pubmed: 29804146 doi: 10.1007/s00415-018-8897-5

Truini A, Biasiotta A, Onesti E, Di Stefano G, Ceccanti M, La Cesa S, Pepe A, Giordano C, Cruccu G, Inghilleri M (2015) Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS. J Neurol 262:1014–1018

pubmed: 25683764 doi: 10.1007/s00415-015-7672-0

Taga A, Schito P, Trapasso MC, Zinno L, Pavesi G (2019) Pain at the onset of amyotrophic lateral sclerosis: a cross-sectional study. Clin Neurol Neurosurg 186:105540

pubmed: 31634749 doi: 10.1016/j.clineuro.2019.105540

Weis J, Katona I, Muller-Newen G, Sommer C, Necula G, Hendrich C, Ludolph AC, Sperfeld AD (2011) Small-fiber neuropathy in patients with ALS. Neurology 76:2024–2029

pubmed: 21646630 doi: 10.1212/WNL.0b013e31821e553a

Gregory R, Mills K, Donaghy M (1993) Progressive sensory nerve dysfunction in amyotrophic lateral sclerosis: a prospective clinical and neurophysiological study. J Neurol 240:309–314

pubmed: 8326338 doi: 10.1007/BF00838169

Dubbioso R, Provitera V, Pacella D, Santoro L, Manganelli F, Nolano M (2023) Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: a prospective longitudinal cohort study. J Neurol 270:4968–4977

pubmed: 37358634 pmcid: 10511550 doi: 10.1007/s00415-023-11832-w

Napoli G, Rubin M, Cutillo G, Schito P, Russo T, Quattrini A, Filippi M, Riva N (2023) Tako-tsubo syndrome in amyotrophic lateral sclerosis: single-center case series and brief literature review. Int J Mol Sci 24:12096

pubmed: 37569475 pmcid: 10418501 doi: 10.3390/ijms241512096

De Marchi F, Franjkic T, Schito P, Russo T, Nimac J, Chami AA, Mele A, Vidatic L, Kriz J, Julien J-P, Apic G, Russell RB, Rogelj B, Cannon JR, Baralle M, Agosta F, Hecimovic S, Mazzini L, Buratti E, Munitic I (2023) Emerging trends in the field of inflammation and proteinopathy in ALS/FTD spectrum disorder. Biomedicines 11:1599

pubmed: 37371694 pmcid: 10295684 doi: 10.3390/biomedicines11061599

Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, Eurals C (2009) Prognostic factors in ALS: a critical review. Amyotrophic Lateral Sclerosis Off Publ World Fed Neurol Res Group Motor Neuron Dis 10:310–323

Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, Scialo C, Soraru G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Chio A, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurro MR, Sabatelli M, Riva N, Logroscino G, Messina S, Fini N, Mandrioli J (2017) Factors predicting survival in ALS: a multicenter Italian study. J Neurol 264:54–63

pubmed: 27778156 doi: 10.1007/s00415-016-8313-y

van Eijk RPA, de Jongh AD, Nikolakopoulos S, McDermott CJ, Eijkemans MJC, Roes KCB, van den Berg LH (2021) An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis Frontotemporal Degener 22:300–307

doi: 10.1080/21678421.2021.1879865

Fournier CN, Bedlack R, Quinn C, Russell J, Beckwith D, Kaminski KH, Tyor W, Hertzberg V, James V, Polak M, Glass JD (2020) Development and validation of the rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS). JAMA Neurol 77:480–488

pubmed: 31886839 doi: 10.1001/jamaneurol.2019.4490

Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A (2015) Prognostic factors for the course of functional status of patients with ALS: a systematic review. J Neurol 262:1407–1423

pubmed: 25385051 doi: 10.1007/s00415-014-7564-8

de Jongh AD, van Eijk RPA, Bakker LA, Bunte TM, Beelen A, van der Meijden C, van Es MA, Visser-Meily JMA, Kruitwagen ET, Veldink JH, van den Berg LH (2023) Development of a rasch-built amyotrophic lateral sclerosis impairment multidomain scale to measure disease progression in ALS. Neurology 101:e602–e612

pubmed: 37311649 pmcid: 10424842 doi: 10.1212/WNL.0000000000207483

Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain J Neurol 135:847–852

doi: 10.1093/brain/awr351

Chio A, Hammond ER, Mora G, Bonito V, Filippini G (2015) Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 86:38–44

pubmed: 24336810 doi: 10.1136/jnnp-2013-306589

Luna J, Couratier P, Lahmadi S, Lautrette G, Fontana A, Tortelli R, Logroscino G, Preux PM, Copetti M, Benoit M (2021) Comparison of the ability of the King’s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Frontotemporal Degener 22:478–485

doi: 10.1080/21678421.2021.1903506

Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Uk-Mnd Lical S, Young C, Shaw PJ, Leigh PN, Al-Chalabi A (2017) Comparison of the King’s and MiToS staging systems for ALS. Amyotrophic Lateral Sclerosis Frontotemporal Degener 18:227–232

doi: 10.1080/21678421.2016.1265565

Dorst J, Chen L, Rosenbohm A, Dreyhaupt J, Hubers A, Schuster J, Weishaupt JH, Kassubek J, Gess B, Meyer T, Weyen U, Hermann A, Winkler J, Grehl T, Hagenacker T, Lingor P, Koch JC, Sperfeld A, Petri S, Grosskreutz J, Metelmann M, Wolf J, Winkler AS, Klopstock T, Boentert M, Johannesen S, Storch A, Schrank B, Zeller D, Liu XL, Tang L, Fan DS, Ludolph AC (2019) Prognostic factors in ALS: a comparison between Germany and China. J Neurol 266:1516–1525

pubmed: 30923935 doi: 10.1007/s00415-019-09290-4

Leighton DJ, Ansari M, Newton J, Parry D, Cleary E, Colville S, Stephenson L, Larraz J, Johnson M, Beswick E, Wong M, Gregory J, Carod Artal J, Davenport R, Duncan C, Morrison I, Smith C, Swingler R, Deary IJ, Porteous M, Aitman TJ, Chandran S, Gorrie GH, Pal S, Lothian Birth Cohorts G, the C-MNDC, (2023) Genotype-phenotype characterisation of long survivors with motor neuron disease in Scotland. J Neurol 270:1702–1712

pubmed: 36515702 doi: 10.1007/s00415-022-11505-0

Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P (2000) Nutritional assessment and survival in ALS patients. Amyotrophic Lateral Sclerosis Other Motor Neur Disord Off Publ Fed Neurol Res Group Motor Neur Dis 1:91–96

Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ (1996) Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 63:130–137

pubmed: 8604660 doi: 10.1093/ajcn/63.1.130

Jawaid A, Murthy SB, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, Simpson E, Harati Y, Strutt AM, York MK, Schulz PE (2010) A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotrophic Lateral Sclerosis Off Publ World Fed Neurol Res Group Motor Neur Dis 11:542–548

Reich-Slotky R, Andrews J, Cheng B, Buchsbaum R, Levy D, Kaufmann P, Thompson JL (2013) Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotrophic Lateral Sclerosis Frontotemporal Degener 14:212–216

doi: 10.3109/21678421.2013.770028

Ahmed RM, Mioshi E, Caga J, Shibata M, Zoing M, Bartley L, Piguet O, Hodges JR, Kiernan MC (2014) Body mass index delineates ALS from FTD: implications for metabolic health. J Neurol 261:1774–1780

pubmed: 24957296 doi: 10.1007/s00415-014-7416-6

Shimizu T, Nakayama Y, Matsuda C, Haraguchi M, Bokuda K, Ishikawa-Takata K, Kawata A, Isozaki E (2019) Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study. J Neurol 266:1412–1420

pubmed: 30868220 doi: 10.1007/s00415-019-09276-2

Cattaneo M, Jesus P, Lizio A, Fayemendy P, Guanziroli N, Corradi E, Sansone V, Leocani L, Filippi M, Riva N, Corcia P, Couratier P, Lunetta C (2022) The hypometabolic state: a good predictor of a better prognosis in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 93:41–47

pubmed: 34353859 doi: 10.1136/jnnp-2021-326184

He J, Fu J, Zhao W, Ren C, Liu P, Chen L, Li D, Tang L, Zhou L, Zhang Y, Ma X, Zhang G, Li N, Fan D (2022) Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis. J Neurol 269:1447–1455

pubmed: 34274994 doi: 10.1007/s00415-021-10716-1

Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1227–1233

pubmed: 19822873 pmcid: 2764728 doi: 10.1212/WNL.0b013e3181bc01a4

Calvo A, Vasta R, Moglia C, Matteoni E, Canosa A, Mattei A, La Mancusa C, Focaraccio L, Mazzini L, Chio A, D’Ovidio F, Manera U (2020) Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. J Neurol 267:1615–1621

pubmed: 32052165 doi: 10.1007/s00415-020-09751-1

Engel M, Glatz C, Helmle C, Young P, Drager B, Boentert M (2021) Respiratory parameters on diagnostic sleep studies predict survival in patients with amyotrophic lateral sclerosis. J Neurol 268:4321–4331

pubmed: 33880611 pmcid: 8505303 doi: 10.1007/s00415-021-10563-0

Alarcan H, Cotet C, Lepine N, Morel J, Vourc’h P, Andres C, Corcia P, Blasco H (2023) Evaluation of arterial blood gas parameters as prognostic markers in amyotrophic lateral sclerosis. Eur J Neurol Off J Eur Fed Neurol Soc 30:1611–1618

Miranda B, Gromicho M, Pereira M, Pinto S, Swash M, de Carvalho M (2020) Diaphragmatic CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALS. J Neurol 267:2123–2129

pubmed: 32253508 doi: 10.1007/s00415-020-09818-z

Xu L, He B, Zhang Y, Chen L, Fan D, Zhan S, Wang S (2021) Prognostic models for amyotrophic lateral sclerosis: a systematic review. J Neurol 268:3361–3370

pubmed: 33694050 doi: 10.1007/s00415-021-10508-7

Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O (2015) Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol 262:1447–1454

pubmed: 25860344 pmcid: 4469087 doi: 10.1007/s00415-015-7731-6

Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66:265–267

pubmed: 16434671 doi: 10.1212/01.wnl.0000194316.91908.8a

Czaplinski A, Yen AA, Simpson EP, Appel SH (2006) Predictability of disease progression in amyotrophic lateral sclerosis. Muscle Nerve 34:702–708

pubmed: 16967489 doi: 10.1002/mus.20658

del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G (2003) Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60:813–819

pubmed: 12629239 doi: 10.1212/01.WNL.0000049472.47709.3B

Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, Hardiman O (2011) Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 76:1263–1269

pubmed: 21464431 doi: 10.1212/WNL.0b013e318214359f

Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, Brunetti M, Ossola I, Lo Presti A, Cammarosano S, Canosa A, Chio A (2015) Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 86:168–173

pubmed: 24769471 doi: 10.1136/jnnp-2013-307223

Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G (2004) Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotrophic Lateral Sclerosis Other Motor Neuron Disorders Off Publ World Fed Neurol Res Group Motor Neur Dis 5:208–212

Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, Bottacchi E, Mutani R, Piemonte VD, Register for ALS (2002) Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59:99–103

pubmed: 12105314 doi: 10.1212/WNL.59.1.99

Grollemund V, Le Chat G, Secchi-Buhour MS, Delbot F, Pradat-Peyre JF, Bede P, Pradat PF (2021) Manifold learning for amyotrophic lateral sclerosis functional loss assessment : development and validation of a prognosis model. J Neurol 268:825–850

pubmed: 32886252 doi: 10.1007/s00415-020-10181-2

Tavazzi E, Daberdaku S, Zandona A, Vasta R, Nefussy B, Lunetta C, Mora G, Mandrioli J, Grisan E, Tarlarini C, Calvo A, Moglia C, Drory V, Gotkine M, Chio A, Di Camillo B, VdARfALSftERRfALS P (2022) Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression. J Neurol 269:3858–3878

pubmed: 35266043 pmcid: 9217910 doi: 10.1007/s00415-022-11022-0

Lehn AC, Dionisio S, Airey CA, Brown H, Blum S, Henderson R (2014) The tibialis anterior response revisited. J Neurol 261:1340–1343

pubmed: 24760338 doi: 10.1007/s00415-014-7329-4

Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Other Motor Neuron Disorders Off Publ World Fed Neurol Res Group Motor Neur Dis 1:293–299

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, Mills K, Mitsumoto H, Nodera H, Shefner J, Swash M (2008) Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 119:497–503

doi: 10.1016/j.clinph.2007.09.143

Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299

pubmed: 11464847 doi: 10.1080/146608200300079536

Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM (2000) Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 57:1171–1176

pubmed: 10927797 doi: 10.1001/archneur.57.8.1171

Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, Grosskreutz J, Hardiman O, Henderson R, Matamala JM, Mitsumoto H, Paulus W, Simon N, Swash M, Talbot K, Turner MR, Ugawa Y, van den Berg LH, Verdugo R, Vucic S, Kaji R, Burke D, Kiernan MC (2020) A proposal for new diagnostic criteria for ALS. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 131:1975–1978

doi: 10.1016/j.clinph.2020.04.005

Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobáGyi T, Rosenfeld J, Silani V, Ince PG, Turner MR (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis Frontotemporal Degener 18:153–174

doi: 10.1080/21678421.2016.1267768

Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP (1996) Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 60:147–151

pubmed: 8708642 pmcid: 1073793 doi: 10.1136/jnnp.60.2.147

Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O (2000) Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 57:109–113

pubmed: 10634456 doi: 10.1001/archneur.57.1.109

Belsh JM, Schiffman PL (1996) The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. J Neurol Sci 139(Suppl):110–116

pubmed: 8899669 doi: 10.1016/0022-510X(96)00088-3

Boelmans K, Kaufmann J, Schmelzer S, Vielhaber S, Kornhuber M, Munchau A, Zierz S, Gaul C (2013) Hirayama disease is a pure spinal motor neuron disorder–a combined DTI and transcranial magnetic stimulation study. J Neurol 260:540–548

pubmed: 23007195 doi: 10.1007/s00415-012-6674-4

Hellmann MA, Kakhlon O, Landau EH, Sadeh M, Giladi N, Schlesinger I, Kidron D, Abramsky O, Reches A, Argov Z, Rabey JM, Chapman J, Rosenmann H, Gal A, Moshe Gomori J, Meiner V, Lossos A (2015) Frequent misdiagnosis of adult polyglucosan body disease. J Neurol. https://doi.org/10.1007/s00415-015-7859-4

doi: 10.1007/s00415-015-7859-4 pubmed: 26194201

Grunseich C, Schindler AB, Chen KL, Bakar D, Mankodi A, Traslavina R, Ray-Chaudhury A, Lehky TJ, Baker EH, Maragakis NJ, Tifft CJ, Fischbeck KH (2015) Peripheral neuropathy in a family with Sandhoff disease and SH3TC2 deficiency. J Neurol 262:1066–1068

pubmed: 25736553 pmcid: 4405612 doi: 10.1007/s00415-015-7683-x

Shibata M, Kasahara H, Makioka K, Ikeda M, Nagashima K, Fujita Y, Ikeda Y (2020) Neurogenic calf amyotrophy with CK elevation by entrapment radiculopathy; clinical, radiological, and pathological analyses of 18 cases. J Neurol 267:3528–3540

pubmed: 32621104 doi: 10.1007/s00415-020-10021-3

Morishima R, Takai K, Ando T, Nakata Y, Shimizu T, Taniguchi M (2019) Brachial multisegmental amyotrophy caused by cervical anterior horn cell disorder associated with a spinal CSF leak: a report of five cases. J Neurol 266:2679–2684

pubmed: 31312956 doi: 10.1007/s00415-019-09469-9

Riva N, Gallia F, Iannaccone S, Corbo M, Terenghi F, Lazzerini A, Cerri F, Comi G, Quattrini A, Nobile-Orazio E (2011) Chronic motor axonal neuropathy. J Periph Nerv Syst JPNS 16:341–346

doi: 10.1111/j.1529-8027.2011.00366.x

Riva N, Iannaccone S, Corbo M, Casellato C, Sferrazza B, Lazzerini A, Scarlato M, Cerri F, Previtali SC, Nobile-Orazio E, Comi G, Quattrini A (2011) Motor nerve biopsy: clinical usefulness and histopathological criteria. Ann Neurol 69:197–201

pubmed: 21280090 doi: 10.1002/ana.22110

Riva N, Gentile F, Cerri F, Gallia F, Podini P, Dina G, Falzone YM, Fazio R, Lunetta C, Calvo A, Logroscino G, Lauria G, Corbo M, Iannaccone S, Chio A, Lazzerini A, Nobile-Orazio E, Filippi M, Quattrini A (2022) Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain J Neurol 145:276–284

doi: 10.1093/brain/awab285

Zoccolella S, Mastronardi A, Scarafino A, Iliceto G, D’Errico E, Fraddosio A, Tempesta I, Morea A, Scaglione G, Introna A, Simone IL (2020) Motor-evoked potentials in amyotrophic lateral sclerosis: potential implications in detecting subclinical UMN involvement in lower motor neuron phenotype. J Neurol 267:3689–3695

pubmed: 32676769 pmcid: 7674351 doi: 10.1007/s00415-020-10073-5

Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, Alderson K, Adams RN (1988) A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24:73–78

pubmed: 2843079 doi: 10.1002/ana.410240113

Cats EA, Jacobs BC, Yuki N, Tio-Gillen AP, Piepers S, Franssen H, van Asseldonk JT, van den Berg LH, van der Pol WL (2010) Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 75:1961–1967

pubmed: 20962291 doi: 10.1212/WNL.0b013e3181ff94c2

Vlam L, Piepers S, Sutedja NA, Jacobs BC, Tio-Gillen AP, Stam M, Franssen H, Veldink JH, Cats EA, Notermans NC, Bloem AC, Wadman RI, van der Pol WL, van den Berg LH (2015) Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study. J Neurol 262:666–673

pubmed: 25549972 doi: 10.1007/s00415-014-7612-4

Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V (2018) CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol 265:510–521

pubmed: 29322259 doi: 10.1007/s00415-017-8730-6

Schreiber S, Spotorno N, Schreiber F, Acosta-Cabronero J, Kaufmann J, Machts J, Debska-Vielhaber G, Garz C, Bittner D, Hensiek N, Dengler R, Petri S, Nestor PJ, Vielhaber S (2018) Significance of CSF NfL and tau in ALS. J Neurol 265:2633–2645

pubmed: 30187162 doi: 10.1007/s00415-018-9043-0

Abu-Rumeileh S, Vacchiano V, Zenesini C, Polischi B, de Pasqua S, Fileccia E, Mammana A, Di Stasi V, Capellari S, Salvi F, Liguori R, Parchi P, BoReAls, (2020) Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol 267:1699–1708

pubmed: 32100123 doi: 10.1007/s00415-020-09761-z

Falzone YM, Domi T, Agosta F, Pozzi L, Schito P, Fazio R, Del Carro U, Barbieri A, Comola M, Leocani L, Comi G, Carrera P, Filippi M, Quattrini A, Riva N (2020) Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J Neurol 267:2272–2280

pubmed: 32306171 pmcid: 7166001 doi: 10.1007/s00415-020-09838-9

Falzone YM, Domi T, Mandelli A, Pozzi L, Schito P, Russo T, Barbieri A, Fazio R, Volonte MA, Magnani G, Del Carro U, Carrera P, Malaspina A, Agosta F, Quattrini A, Furlan R, Filippi M, Riva N (2022) Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol Off J Eur Fed Neurol Soc 29:1930–1939

Peng L, Wan L, Liu M, Long Z, Chen D, Yuan X, Tang Z, Fu Y, Zhu S, Lei L, Wang C, Peng H, Shi Y, He L, Yuan H, Wan N, Hou X, Xia K, Li J, Chen C, Qiu R, Tang B, Chen Z, Jiang H (2023) Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study. J Neurol 270:4248–4261

pubmed: 37184660 doi: 10.1007/s00415-023-11741-y

Brousse M, Delaby C, De La Cruz E, Kuhle J, Benkert P, Mondesert E, Ginestet N, Hirtz C, Camu W, Lehmann S, Esselin F (2023) Serum neurofilament light chain cut-off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis. Eu J Neurol Off J Eur Fed Neurol Soc 30:1919–1927

Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chio A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette Valor S, Group OLEW (2022) Trial of Antisense oligonucleotide tofersen for SOD1 ALS. New Engl J Med 387:1099–1110

pubmed: 36129998 doi: 10.1056/NEJMoa2204705

Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A (2018) Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 84:130–139

pubmed: 30014505 doi: 10.1002/ana.25276

De Schaepdryver M, Goossens J, De Meyer S, Jeromin A, Masrori P, Brix B, Claeys KG, Schaeverbeke J, Adamczuk K, Vandenberghe R, Van Damme P, Poesen K (2019) Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann Clin Transl Neurol 6:1971–1979

pubmed: 31518073 pmcid: 6801162 doi: 10.1002/acn3.50890

Bjornevik K, O’Reilly EJ, Molsberry S, Kolonel LN, Le Marchand L, Paganoni S, Schwarzschild MA, Benkert P, Kuhle J, Ascherio A (2021) Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology 97:e1466-1474

pubmed: 34380747 pmcid: 8575132 doi: 10.1212/WNL.0000000000012632

Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, Tournoy J, Van Damme P, Poesen K (2019) Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 90:1338–1346

pubmed: 31175169

Thompson AG, Gray E, Bampton A, Raciborska D, Talbot K, Turner MR (2019) CSF chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 90:1215–1220

pubmed: 31123140 doi: 10.1136/jnnp-2019-320442

Shepheard SR, Karnaros V, Benyamin B, Schultz DW, Dubowsky M, Wuu J, Chataway T, Malaspina A, Benatar M, Rogers ML (2022) Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis. Eur J Neurol Off J Eur Fed Neurol Soc 29:990–999

Lunetta C, Lizio A, Gerardi F, Tarlarini C, Filippi M, Riva N, Tremolizzo L, Diamanti S, Dellanoce CC, Mosca L, Sansone VA, Campolo J (2020) Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis. J Neurol 267:3609–3616

pubmed: 32638112 doi: 10.1007/s00415-020-10047-7

Ludolph A, Dupuis L, Kasarskis E, Steyn F, Ngo S, McDermott C (2023) Nutritional and metabolic factors in amyotrophic lateral sclerosis. Nat Rev Neurol 19:511–524

pubmed: 37500993 doi: 10.1038/s41582-023-00845-8

Ludolph AC, Dorst J, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, Meyer T, Petri S, Hermann A, Emmer A, Grosskreutz J, Grehl T, Zeller D, Boentert M, Schrank B, Prudlo J, Winkler AS, Gorbulev S, Roselli F, Schuster J, Dupuis L, Group L-AS (2020) Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol 87:206–216

pubmed: 31849093 doi: 10.1002/ana.25661

Michels S, Kurz D, Rosenbohm A, Peter RS, Just S, Bazner H, Bortlein A, Dettmers C, Gold HJ, Kohler A, Naumann M, Ratzka P, Ludolph AC, Rothenbacher D, Nagel G, Dorst J, Group ALSRSS (2023) Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registry. J Neurol 270:3082–3090

pubmed: 36853389 pmcid: 10193299 doi: 10.1007/s00415-023-11630-4

Lunetta C, Lizio A, Tremolizzo L, Ruscica M, Macchi C, Riva N, Weydt P, Corradi E, Magni P, Sansone V (2018) Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. J Neurol 265:3001–3008

pubmed: 30350169 doi: 10.1007/s00415-018-9093-3

Dolinar A, Koritnik B, Glavac D, Ravnik-Glavac M (2019) Circular RNAs as potential blood biomarkers in amyotrophic lateral sclerosis. Mol Neurobiol 56:8052–8062

pubmed: 31175544 pmcid: 6834740 doi: 10.1007/s12035-019-1627-x

Filippi M, Agosta F, Grosskreutz J, Benatar M, Kassubek J, Verstraete E, Turner MR, Neuroimaging Society in ALS (2015) Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 14:786–788

pubmed: 26194923 doi: 10.1016/S1474-4422(15)00134-9

Agosta F, Spinelli EG, Filippi M (2018) Neuroimaging in amyotrophic lateral sclerosis: current and emerging uses. Expert Rev Neurother 18:395–406

pubmed: 29630421 doi: 10.1080/14737175.2018.1463160

Spinelli EG, Riva N, Rancoita PMV, Schito P, Doretti A, Poletti B, Di Serio C, Silani V, Filippi M, Agosta F (2020) Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis. NeuroImage Clin 27:102315

pubmed: 32593977 pmcid: 7327879 doi: 10.1016/j.nicl.2020.102315

Fabes J, Matthews L, Filippini N, Talbot K, Jenkinson M, Turner MR (2017) Quantitative FLAIR MRI in amyotrophic lateral sclerosis. Acad Radiol 24:1187–1194

pubmed: 28572001 pmcid: 5605225 doi: 10.1016/j.acra.2017.04.008

Roeben B, Wilke C, Bender B, Ziemann U, Synofzik M (2019) The motor band sign in ALS: presentations and frequencies in a consecutive series of ALS patients. J Neurol Sci 406:116440

pubmed: 31521959 doi: 10.1016/j.jns.2019.116440

Cardenas-Blanco A, Machts J, Acosta-Cabronero J, Kaufmann J, Abdulla S, Kollewe K, Petri S, Heinze HJ, Dengler R, Vielhaber S, Nestor PJ (2014) Central white matter degeneration in bulbar- and limb-onset amyotrophic lateral sclerosis. J Neurol 261:1961–1967

pubmed: 25059391 doi: 10.1007/s00415-014-7434-4

Zhang J, Yin X, Zhao L, Evans AC, Song L, Xie B, Li H, Luo C, Wang J (2014) Regional alterations in cortical thickness and white matter integrity in amyotrophic lateral sclerosis. J Neurol 261:412–421

pubmed: 24452838 doi: 10.1007/s00415-013-7215-5

Caiazzo G, Corbo D, Trojsi F, Piccirillo G, Cirillo M, Monsurro MR, Esposito F, Tedeschi G (2014) Distributed corpus callosum involvement in amyotrophic lateral sclerosis: a deterministic tractography study using q-ball imaging. J Neurol 261:27–36

pubmed: 24126610 doi: 10.1007/s00415-013-7144-3

Spinelli EG, Agosta F, Ferraro PM, Querin G, Riva N, Bertolin C, Martinelli I, Lunetta C, Fontana A, Soraru G, Filippi M (2019) Brain MRI shows white matter sparing in Kennedy’s disease and slow-progressing lower motor neuron disease. Hum Brain Mapp 40:3102–3112

pubmed: 30924230 pmcid: 6865482 doi: 10.1002/hbm.24583

Rosenbohm A, Muller HP, Hubers A, Ludolph AC, Kassubek J (2016) Corticoefferent pathways in pure lower motor neuron disease: a diffusion tensor imaging study. J Neurol 263:2430–2437

pubmed: 27624123 doi: 10.1007/s00415-016-8281-2

Agosta F, Ferraro PM, Riva N, Spinelli EG, Chio A, Canu E, Valsasina P, Lunetta C, Iannaccone S, Copetti M, Prudente E, Comi G, Falini A, Filippi M (2016) Structural brain correlates of cognitive and behavioral impairment in MND. Hum Brain Mapp 37:1614–1626

pubmed: 26833930 pmcid: 6867462 doi: 10.1002/hbm.23124

Bede P, Lule D, Muller HP, Tan EL, Dorst J, Ludolph AC, Kassubek J (2023) Presymptomatic grey matter alterations in ALS kindreds: a computational neuroimaging study of asymptomatic C9orf72 and SOD1 mutation carriers. J Neurol 270:4235–4247

pubmed: 37178170 pmcid: 10421803 doi: 10.1007/s00415-023-11764-5

Schuster C, Kasper E, Machts J, Bittner D, Kaufmann J, Benecke R, Teipel S, Vielhaber S, Prudlo J (2014) Longitudinal course of cortical thickness decline in amyotrophic lateral sclerosis. J Neurol 261:1871–1880

pubmed: 25022938 doi: 10.1007/s00415-014-7426-4

Steinbach R, Loewe K, Kaufmann J, Machts J, Kollewe K, Petri S, Dengler R, Heinze HJ, Vielhaber S, Schoenfeld MA, Stoppel CM (2015) Structural hallmarks of amyotrophic lateral sclerosis progression revealed by probabilistic fiber tractography. J Neurol. https://doi.org/10.1007/s00415-015-7841-1

doi: 10.1007/s00415-015-7841-1 pubmed: 26159103

Muller HP, Behler A, Munch M, Dorst J, Ludolph AC, Kassubek J (2023) Sequential alterations in diffusion metrics as correlates of disease severity in amyotrophic lateral sclerosis. J Neurol 270:2308–2313

pubmed: 36763176 pmcid: 10025190 doi: 10.1007/s00415-023-11582-9

Khamaysa M, Lefort M, Pelegrini-Issac M, Lackmy-Vallee A, Preuilh A, Devos D, Rolland AS, Desnuelle C, Chupin M, Marchand-Pauvert V, Querin G, Pradat PF, Pulse study g, (2023) Comparison of spinal magnetic resonance imaging and classical clinical factors in predicting motor capacity in amyotrophic lateral sclerosis. J Neurol 270:3885–3895

pubmed: 37103756 doi: 10.1007/s00415-023-11727-w

Toh C, Keslake A, Payne T, Onwuegbuzie A, Harding J, Baster K, Hoggard N, Shaw PJ, Wilkinson ID, Jenkins TM (2023) Analysis of brain and spinal MRI measures in a common domain to investigate directional neurodegeneration in motor neuron disease. J Neurol 270:1682–1690

pubmed: 36509983 doi: 10.1007/s00415-022-11520-1

Canosa A, Moglia C, Manera U, Vasta R, Torrieri MC, Arena V, D'Ovidio F, Palumbo F, Zucchetti JP, Iazzolino B, Peotta L, Calvo A, Pagani M, Chio A (2020) Metabolic brain changes across different levels of cognitive impairment in ALS: a (18)F-FDG-PET study. J Neurol Neurosurg Psychiatry

Canosa A, Martino A, Giuliani A, Moglia C, Vasta R, Grassano M, Palumbo F, Cabras S, Di Pede F, De Mattei F, Matteoni E, Polverari G, Manera U, Calvo A, Pagani M, Chio A (2023) Brain metabolic differences between pure bulbar and pure spinal ALS: a 2-[(18)F]FDG-PET study. J Neurol 270:953–959

pubmed: 36322237 doi: 10.1007/s00415-022-11445-9

Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, Robberecht W, Van Damme P (2014) Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol 71:553–561

pubmed: 24615479 doi: 10.1001/jamaneurol.2014.62

De Vocht J, Blommaert J, Devrome M, Radwan A, Van Weehaeghe D, De Schaepdryver M, Ceccarini J, Rezaei A, Schramm G, van Aalst J, Chio A, Pagani M, Stam D, Van Esch H, Lamaire N, Verhaegen M, Mertens N, Poesen K, van den Berg LH, van Es MA, Vandenberghe R, Vandenbulcke M, Van den Stock J, Koole M, Dupont P, Van Laere K, Van Damme P (2020) Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion. JAMA Neurol 77:1008–1017

pubmed: 32421156 doi: 10.1001/jamaneurol.2020.1087

Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, Cudkowicz ME, Hooker JM, Atassi N (2015) Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. NeuroImage Clin 7:409–414

pubmed: 25685708 pmcid: 4310932 doi: 10.1016/j.nicl.2015.01.009

Alshikho MJ, Zurcher NR, Loggia ML, Cernasov P, Reynolds B, Pijanowski O, Chonde DB, Izquierdo Garcia D, Mainero C, Catana C, Chan J, Babu S, Paganoni S, Hooker JM, Atassi N (2018) Integrated magnetic resonance imaging and [(11) C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol 83:1186–1197

pubmed: 29740862 pmcid: 6105567 doi: 10.1002/ana.25251

Tondo G, Iaccarino L, Cerami C, Vanoli GE, Presotto L, Masiello V, Coliva A, Salvi F, Bartolomei I, Mosca L, Lunetta C, Perani D (2020) (11) C-PK11195 PET-based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis. Ann Clin Transl Neurol 7:1513–1523

pubmed: 32762033 pmcid: 7480909 doi: 10.1002/acn3.51112

Mitsumoto H, Brooks BR, Silani V (2014) Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 13:1127–1138

pubmed: 25316019 doi: 10.1016/S1474-4422(14)70129-2

Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330:585–591

pubmed: 8302340 doi: 10.1056/NEJM199403033300901

Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347:1425–1431

pubmed: 8676624 doi: 10.1016/S0140-6736(96)91680-3

Mandrioli J, Malerba SA, Beghi E, Fini N, Fasano A, Zucchi E, De Pasqua S, Guidi C, Terlizzi E, Sette E, Ravasio A, Casmiro M, Salvi F, Liguori R, Zinno L, Handouk Y, Rizzi R, Borghi A, Rinaldi R, Medici D, Santangelo M, Granieri E, Mussuto V, Aiello M, Ferro S, Vinceti M, Group E (2018) Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol 265:817–827

pubmed: 29404735 doi: 10.1007/s00415-018-8778-y

Jayaprakash K, Glasmacher SA, Pang B, Beswick E, Mehta AR, Dakin R, Newton J, Chandran S, Pal S, Consortium C-M (2020) Riluzole prescribing, uptake and treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland. J Neurol 267:2459–2461

pubmed: 32447548 pmcid: 7359150 doi: 10.1007/s00415-020-09919-9

Writing G, Edaravone ALSSG (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:505–512

doi: 10.1016/S1474-4422(17)30115-1

Lunetta C, Moglia C, Lizio A, Caponnetto C, Dubbioso R, Giannini F, Mata S, Mazzini L, Sabatelli M, Siciliano G, Simone IL, Soraru G, Toriello A, Trojsi F, Vedovello M, D’Ovidio F, Filippi M, Calvo A, ESG, (2020) The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol 267:3258–3267

pubmed: 32556567 doi: 10.1007/s00415-020-09993-z

Distaso E, Milella G, Mezzapesa DM, Introna A, D’Errico E, Fraddosio A, Zoccolella S, Dicuonzo F, Simone IL (2021) Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone. J Neurol 268:3307–3315

pubmed: 33655342 pmcid: 8357666 doi: 10.1007/s00415-021-10495-9

Massey TH, Robertson NP (2018) Repurposing drugs to treat neurological diseases. J Neurol 265:446–448

pubmed: 29322257 pmcid: 5808092 doi: 10.1007/s00415-018-8732-z

Chio A, Mazzini L, Mora G (2020) Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 167:107986

pubmed: 32062193 doi: 10.1016/j.neuropharm.2020.107986

Dalla Bella E, Bersano E, Antonini G, Borghero G, Capasso M, Caponnetto C, Chio A, Corbo M, Filosto M, Giannini F, Spataro R, Lunetta C, Mandrioli J, Messina S, Monsurro MR, Mora G, Riva N, Rizzi R, Siciliano G, Silani V, Simone I, Soraru G, Tugnoli V, Verriello L, Volanti P, Furlan R, Nolan JM, Abgueguen E, Tramacere I, Lauria G (2021) The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain J Neurol 144:2635–2647

doi: 10.1093/brain/awab167

Sassi S, Bianchi E, Diamanti L, Tornabene D, Sette E, Medici D, Mata S, Leccese D, Sperti M, Martinelli I, Ghezzi A, Mandrioli J, Iuzzolino VV, Dubbioso R, Trojsi F, Passaniti C, D’Alvano G, Filosto M, Padovani A, Mazzini L, De Marchi F, Zinno L, Nuredini A, Bongioanni P, Dolciotti C, Canali E, Toschi G, Petrucci A, Perna A, Riso V, Inghilleri M, Libonati L, Cambieri C, Pupillo E (2023) Retrospective observational study on the use of acetyl-L-carnitine in ALS. J Neurol 270:5344–5357

pubmed: 37378756 pmcid: 10576701 doi: 10.1007/s00415-023-11844-6

Lo Giudice M, Cocco A, Reggiardo G, Lalli S, Albanese A (2023) Tauro-Urso-deoxycholic acid trials in amyotrophic lateral sclerosis: what is achieved and what to expect. Clin Drug Investig 43:893–903

pubmed: 37973672 pmcid: 10700186 doi: 10.1007/s40261-023-01324-0

Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME (2020) Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 383:919–930

pubmed: 32877582 pmcid: 9134321 doi: 10.1056/NEJMoa1916945

Amylyx Pharma (2024) Amylyx Pharmaceuticals announces topline results from global phase 3 PHOENIX Trial of AMX0035 in ALS. In: Amylyx to Host Investor Conference Call Today, March 8, at 8:00 a.m. ET.

TUDCA-ALS consortium (2024) The TUDCA-ALS consortium announces top-line results from the European phase 3 clinical trial of TUDCA in patients with amyotrophic lateral sclerosis (ALS).

Aizawa H, Kato H, Oba K, Kawahara T, Okubo Y, Saito T, Naito M, Urushitani M, Tamaoka A, Nakamagoe K, Ishii K, Kanda T, Katsuno M, Atsuta N, Maeda Y, Nagai M, Nishiyama K, Ishiura H, Toda T, Kawata A, Abe K, Yabe I, Takahashi-Iwata I, Sasaki H, Warita H, Aoki M, Sobue G, Mizusawa H, Matsuyama Y, Haga T, Kwak S (2022) Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J Neurol 269:885–896

pubmed: 34191081 doi: 10.1007/s00415-021-10670-y

Thonhoff JR, Berry JD, Macklin EA, Beers DR, Mendoza PA, Zhao W, Thome AD, Triolo F, Moon JJ, Paganoni S, Cudkowicz M, Appel SH (2022) Combined regulatory T-Lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 9

Lunetta C, Lizio A, Cabona C, Gerardi F, Sansone VA, Corbo M, Scialo C, Angelucci E, Gualandi F, Marenco P, Grillo G, Cairoli R, Cesana C, Saccardi R, Melazzini MG, Mancardi G, Caponnetto C (2022) A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis. J Neurol 269:5337–5346

pubmed: 35596795 doi: 10.1007/s00415-022-11185-w

Mandrioli J, D’Amico R, Zucchi E, De Biasi S, Banchelli F, Martinelli I, Simonini C, Lo Tartaro D, Vicini R, Fini N, Gianferrari G, Pinti M, Lunetta C, Gerardi F, Tarlarini C, Mazzini L, De Marchi F, Scognamiglio A, Soraru G, Fortuna A, Lauria G, Bella ED, Caponnetto C, Meo G, Chio A, Calvo A, Cossarizza A (2023) Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis. Nat Commun 14:4970

pubmed: 37591957 pmcid: 10435464 doi: 10.1038/s41467-023-40734-8

Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamaki M, Garratt C, Al-Chalabi A, investigators R, (2021) Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 20:821–831

pubmed: 34536404 doi: 10.1016/S1474-4422(21)00242-8

Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, Corcia P, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA (2023) COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success. Amyotrophic Lateral Sclerosis Frontotemporal Degener 24:523–534

doi: 10.1080/21678421.2023.2216223

Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA (2022) Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med 28:104–116

pubmed: 35075293 pmcid: 8799464 doi: 10.1038/s41591-021-01615-z

Boros BD, Schoch KM, Kreple CJ, Miller TM (2022) Antisense oligonucleotides for the study and treatment of ALS. Neurotherapeut J Am Soc Exper NeuroTherapeut 19:1145–1158

doi: 10.1007/s13311-022-01247-2

Khamaysa M, Pradat PF (2022) Status of ALS treatment, insights into therapeutic challenges and dilemmas. J Personal Med 12:1601

doi: 10.3390/jpm12101601

Zhu Q, Xu D, Huang H, Li D, Yang D, Zhou J, Zhao Y (2023) The safety and effectiveness of high-calorie therapy for treating amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol 270:4729–4743

pubmed: 37369861 pmcid: 10511594 doi: 10.1007/s00415-023-11838-4

Kalron A, Mahameed I, Weiss I, Rosengarten D, Balmor GR, Heching M, Kramer MR (2021) Effects of a 12-week combined aerobic and strength training program in ambulatory patients with amyotrophic lateral sclerosis: a randomized controlled trial. J Neurol 268:1857–1866

pubmed: 33388929 doi: 10.1007/s00415-020-10354-z

Talbot K, Feneberg E, Scaber J, Thompson AG, Turner MR (2018) Amyotrophic lateral sclerosis: the complex path to precision medicine. J Neurol 265:2454–2462

pubmed: 30054789 pmcid: 6182683 doi: 10.1007/s00415-018-8983-8

Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O (2003) An outcome study of riluzole in amyotrophic lateral sclerosis–a population-based study in Ireland, 1996–2000. J Neurol 250:473–479

pubmed: 12700914 doi: 10.1007/s00415-003-1026-z

Van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, Van der Graaff MM, Wokke JH, Van den Berg LH (2005) Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 65:1264–1267

pubmed: 16247055 doi: 10.1212/01.wnl.0000180717.29273.12

Rooney J, Byrne S, Heverin M, Tobin K, Dick A, Donaghy C, Hardiman O (2015) A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry 86:496–501

pubmed: 25550416 doi: 10.1136/jnnp-2014-309601

Ng L, Khan F, Mathers S (2009) Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochr Datab System Rev:CD007425

Hrastelj J, Robertson NP (2015) Improving survival in amyotrophic lateral sclerosis: future treatments in a modern service. J Neurol 262:1791–1793

pubmed: 26067220 doi: 10.1007/s00415-015-7811-7

Katzberg HD (2015) Neurogenic muscle cramps. J Neurol 262:1814–1821

pubmed: 25673127 doi: 10.1007/s00415-015-7659-x

Riva N, Mora G, Soraru G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, Group CS (2019) Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 18:155–164

pubmed: 30554828 doi: 10.1016/S1474-4422(18)30406-X

Young CA, Ellis C, Johnson J, Sathasivam S, Pih N (2011) Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochr Database System Rev:CD006981

Amador Mdel M, Assouline A, Gonzalez-Bermejo J, Pradat PF (2015) Radiotherapy treatment of sialorrhea in patients with amyotrophic lateral sclerosis requiring non-invasive ventilation. J Neurol 262:1981–1983

pubmed: 26174654 doi: 10.1007/s00415-015-7848-7

Desport JC, Torny F, Lacoste M, Preux PM, Couratier P (2005) Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2:202–207

pubmed: 16909026 doi: 10.1159/000089626

Wada A, Kawakami M, Liu M, Otaka E, Nishimura A, Liu F, Otsuka T (2015) Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS). J Neurol

Allen JA, Chen R, Ajroud-Driss S, Sufit RL, Heller S, Siddique T, Wolfe L (2013) Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: a retrospective study of complications and outcome. Amyotrophic Lateral Sclerosis Frontotemporal Degener 14:308–314

doi: 10.3109/21678421.2012.751613

Blondet A, Lebigot J, Nicolas G, Boursier J, Person B, Laccoureye L, Aube C (2010) Radiologic versus endoscopic placement of percutaneous gastrostomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy, and survival. J Vasc Interven Radiolo JVIR 21:527–533

doi: 10.1016/j.jvir.2009.11.022

Dorst J, Dupuis L, Petri S, Kollewe K, Abdulla S, Wolf J, Weber M, Czell D, Burkhardt C, Hanisch F, Vielhaber S, Meyer T, Frisch G, Kettemann D, Grehl T, Schrank B, Ludolph AC (2015) Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol 262:849–858

pubmed: 25618254 doi: 10.1007/s00415-015-7646-2

Thompson AG, Blackwell V, Marsden R, Millard E, Lawson C, Nickol AH, East JE, Talbot K, Allan PJ, Turner MR (2017) A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS. Amyotrophic Lateral Sclerosis Frontotemporal Degener 18:243–248

doi: 10.1080/21678421.2016.1274330

ProGas Study G (2015) Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol 14:702–709

doi: 10.1016/S1474-4422(15)00104-0

Pfeffer G, Povitz M, Gibson GJ, Chinnery PF (2015) Diagnosis of muscle diseases presenting with early respiratory failure. J Neurol 262:1101–1114

pubmed: 25377282 doi: 10.1007/s00415-014-7526-1

Capozzo R, Quaranta VN, Pellegrini F, Fontana A, Copetti M, Carratu P, Panza F, Cassano A, Falcone VA, Tortelli R, Cortese R, Simone IL, Resta O, Logroscino G (2015) Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol 262:593–603

pubmed: 25522696 doi: 10.1007/s00415-014-7613-3

Di PWC, Di PSGC (2015) Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol 14:883–892

doi: 10.1016/S1474-4422(15)00152-0

Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ (2006) Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 5:140–147

pubmed: 16426990 doi: 10.1016/S1474-4422(05)70326-4

Jacobs TL, Brown DL, Baek J, Migda EM, Funckes T, Gruis KL (2016) Trial of early noninvasive ventilation for ALS: a pilot placebo-controlled study. Neurology 87:1878–1883

pubmed: 27581221 pmcid: 5100714 doi: 10.1212/WNL.0000000000003158

Rafiq MK, Bradburn M, Proctor AR, Billings CG, Bianchi S, McDermott CJ, Shaw PJ (2015) A preliminary randomized trial of the mechanical insufflator-exsufflator versus breath-stacking technique in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Frontotemporal Degener 16:448–455

doi: 10.3109/21678421.2015.1051992

Boentert M, Brenscheidt I, Glatz C, Young P (2015) Effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with amyotrophic lateral sclerosis. J Neurol. https://doi.org/10.1007/s00415-015-7822-4

doi: 10.1007/s00415-015-7822-4 pubmed: 26076745

Berlowitz DJ, Howard ME, Fiore JF Jr, Vander Hoorn S, O’Donoghue FJ, Westlake J, Smith A, Beer F, Mathers S, Talman P (2015) Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2014-310055

doi: 10.1136/jnnp-2014-310055 pubmed: 25857659

Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, Pradat PF, Silani V, Tomik B, Group EW (2007) Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotrophic Lateral Sclerosis : Off Publ World Fed Neurol Res Group Motor Neuron Dis 8:195–213

doi: 10.1080/17482960701262376

Wu JM, Tam MT, Buch K, Khairati F, Wilson L, Bannerman E, Guerrero A, Eisen A, Toyer W, Stevenson T, Robillard JM (2022) The impact of respite care from the perspectives and experiences of people with amyotrophic lateral sclerosis and their care partners: a qualitative study. BMC Palliat Care 21:26

pubmed: 35227242 pmcid: 8886844 doi: 10.1186/s12904-022-00919-2

Oberstadt MCF, Esser P, Classen J, Mehnert A (2018) Alleviation of psychological distress and the improvement of quality of life in patients with amyotrophic lateral sclerosis: adaptation of a short-term psychotherapeutic intervention. Front Neurol 9:231

pubmed: 29713302 pmcid: 5911468 doi: 10.3389/fneur.2018.00231

Pugliese R, Sala R, Regondi S, Beltrami B, Lunetta C (2022) Emerging technologies for management of patients with amyotrophic lateral sclerosis: from telehealth to assistive robotics and neural interfaces. J Neurol 269:2910–2921

pubmed: 35059816 pmcid: 8776511 doi: 10.1007/s00415-022-10971-w

Glasmacher SA, Larraz J, Mehta AR, Kearns PKA, Wong M, Newton J, Davenport R, Gorrie G, Morrison I, Carod Artal J, Chandran S, Pal S, Consortium C-M (2021) The immediate impact of the COVID-19 pandemic on motor neuron disease services and mortality in Scotland. J Neurol 268:2038–2040

pubmed: 32889618 doi: 10.1007/s00415-020-10207-9

Costamagna G, Abati E, Bresolin N, Comi GP, Corti S (2021) Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic. J Neurol 268:1580–1591

pubmed: 32804279 doi: 10.1007/s00415-020-10149-2

Londral A (2022) Assistive technologies for communication empower patients with ALS to generate and self-report health data. Front Neurol 13:867567

pubmed: 35557618 pmcid: 9090469 doi: 10.3389/fneur.2022.867567

Eicher C, Kiselev J, Brukamp K, Kiemel D, Spittel S, Maier A, Oleimeulen U, Greuèl M (2019) Expectations and Concerns Emerging from Experiences with Assistive Technology for ALS Patients. Universal Access in Human-Computer Interaction. Springer International Publishing, Cham, pp 57–68

Linse K, Aust E, Joos M, Hermann A (2018) Communication matters-pitfalls and promise of hightech communication devices in palliative care of severely physically disabled patients with amyotrophic lateral sclerosis. Front Neurol 9:603

pubmed: 30100896 pmcid: 6072854 doi: 10.3389/fneur.2018.00603

Fernandes F, Barbalho I, Bispo Junior A, Alves L, Nagem D, Lins H, Arrais Junior E, Coutinho KD, Morais AHF, Santos JPQ, Machado GM, Henriques J, Teixeira C, Dourado Junior MET, Lindquist ARR, Valentim RAM (2023) Digital alternative communication for individuals with amyotrophic lateral sclerosis: what we have. J Clin Med. https://doi.org/10.3390/jcm12165235

doi: 10.3390/jcm12165235 pubmed: 38202187 pmcid: 10779723

Garibaldi M, Siciliano G, Antonini G (2021) Telemedicine for neuromuscular disorders during the COVID-19 outbreak. J Neurol 268:1–4

pubmed: 32651671 doi: 10.1007/s00415-020-10063-7

Helleman J, Bakers JNE, Pirard E, van den Berg LH, Visser-Meily JMA, Beelen A (2022) Home-monitoring of vital capacity in people with a motor neuron disease. J Neurol 269:3713–3722

pubmed: 35129626 pmcid: 9217878 doi: 10.1007/s00415-022-10996-1

Kudritzki V, Howard IM (2023) Telehealth-based exercise in amyotrophic lateral sclerosis. Front Neurol 14:1238916

pubmed: 37564731 pmcid: 10410446 doi: 10.3389/fneur.2023.1238916

Diment LE, Thompson MS, Bergmann JHM (2017) Clinical efficacy and effectiveness of 3D printing: a systematic review. BMJ Open 7:e016891

pubmed: 29273650 pmcid: 5778284 doi: 10.1136/bmjopen-2017-016891

Jabil (2024) Top 3D Printing Challenges (And How to Overcome Them)

Holdom CJ, van Unnik JWJ, van Eijk RPA, van den Berg LH, Henderson RD, Ngo ST, Steyn FJ (2023) Use of hip- versus wrist-based actigraphy for assessing functional decline and disease progression in patients with motor neuron disease. J Neurol 270:2597–2605

pubmed: 36740646 pmcid: 10129939 doi: 10.1007/s00415-023-11584-7

Beswick E, Fawcett T, Hassan Z, Forbes D, Dakin R, Newton J, Abrahams S, Carson A, Chandran S, Perry D, Pal S (2022) A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease. J Neurol 269:6254–6268

pubmed: 35945397 pmcid: 9363141 doi: 10.1007/s00415-022-11312-7

Godkin FE, Turner E, Demnati Y, Vert A, Roberts A, Swartz RH, McLaughlin PM, Weber KS, Thai V, Beyer KB, Cornish B, Abrahao A, Black SE, Masellis M, Zinman L, Beaton D, Binns MA, Chau V, Kwan D, Lim A, Munoz DP, Strother SC, Sunderland KM, Tan B, McIlroy WE, Van Ooteghem K (2022) Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disease. J Neurol 269:2673–2686

pubmed: 34705114 doi: 10.1007/s00415-021-10831-z

Johnson SA, Karas M, Burke KM, Straczkiewicz M, Scheier ZA, Clark AP, Iwasaki S, Lahav A, Iyer AS, Onnela JP, Berry JD (2023) Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures. NPJ Digit Med 6:34

pubmed: 36879025 pmcid: 9987377 doi: 10.1038/s41746-023-00778-y

Helleman J, Johnson B, Holdom C, Hobson E, Murray D, Steyn FJ, Ngo ST, Henders A, Lokeshappa MB, Visser-Meily JMA, van den Berg LH, Hardiman O, Beelen A, McDermott C, van Eijk RPA (2022) Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease: an international survey. J Neurol 269:6003–6013

pubmed: 35849154 pmcid: 9294855 doi: 10.1007/s00415-022-11273-x

Proietti T, O’Neill C, Gerez L, Cole T, Mendelowitz S, Nuckols K, Hohimer C, Lin D, Paganoni S, Walsh C (2023) Restoring arm function with a soft robotic wearable for individuals with amyotrophic lateral sclerosis. Sci Transl Med 15:eadd1504

pubmed: 36724237 doi: 10.1126/scitranslmed.add1504

Vansteensel MJ, Klein E, van Thiel G, Gaytant M, Simmons Z, Wolpaw JR, Vaughan TM (2023) Towards clinical application of implantable brain-computer interfaces for people with late-stage ALS: medical and ethical considerations. J Neurol 270:1323–1336

pubmed: 36450968 doi: 10.1007/s00415-022-11464-6

WYSS CENTER (2024) ABILITY - An implantable brain-computer interface (BCI) to restore movement and communication

CENTER W (2024) NeuroKey™ - Real-time neural signal processing platform

Seitzer F, Kahrass H, Neitzke G, Strech D (2015) The full spectrum of ethical issues in the care of patients with ALS: a systematic qualitative review. J Neurol. https://doi.org/10.1007/s00415-015-7867-4

doi: 10.1007/s00415-015-7867-4 pubmed: 26223806

Shaw J, Brown R, Heinrich P, Dunn S (2013) Doctors’ experience of stress during simulated bad news consultations. Patient Educ Couns 93:203–208

pubmed: 23850183 doi: 10.1016/j.pec.2013.06.009

Shaw JM, Brown RF, Dunn SM (2013) A qualitative study of stress and coping responses in doctors breaking bad news. Patient Educ Couns 91:243–248

pubmed: 23206660 doi: 10.1016/j.pec.2012.11.006

Benditt JO, Smith TS, Tonelli MR (2001) Empowering the individual with ALS at the end-of-life: disease-specific advance care planning. Muscle Nerve 24:1706–1709

pubmed: 11745983 doi: 10.1002/mus.1208

Connolly S, Galvin M, Hardiman O (2015) End-of-life management in patients with amyotrophic lateral sclerosis. Lancet Neurol 14:435–442

pubmed: 25728958 doi: 10.1016/S1474-4422(14)70221-2

Greenaway LP, Martin NH, Lawrence V, Janssen A, Al-Chalabi A, Leigh PN, Goldstein LH (2015) Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients’ perspectives. J Neurol 262:1002–1013

pubmed: 25683760 doi: 10.1007/s00415-015-7665-z

Diagnosis ETFo, Management of Amyotrophic Lateral S, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur J Neurol Off J Eur Fed Neurol Soc 19:360–375

Munroe CA, Sirdofsky MD, Kuru T, Anderson ED (2007) End-of-life decision making in 42 patients with amyotrophic lateral sclerosis. Respir Care 52:996–999

pubmed: 17650354

Lule D, Ehlich B, Lang D, Sorg S, Heimrath J, Kubler A, Birbaumer N, Ludolph AC (2013) Quality of life in fatal disease: the flawed judgement of the social environment. J Neurol 260:2836–2843

pubmed: 23989341 doi: 10.1007/s00415-013-7068-y

Maessen M, Veldink JH, Onwuteaka-Philipsen BD, Hendricks HT, Schelhaas HJ, Grupstra HF, van der Wal G, van den Berg LH (2014) Euthanasia and physician-assisted suicide in amyotrophic lateral sclerosis: a prospective study. J Neurol 261:1894–1901

pubmed: 25022937 doi: 10.1007/s00415-014-7424-6

Lule D, Nonnenmacher S, Sorg S, Heimrath J, Hautzinger M, Meyer T, Kubler A, Birbaumer N, Ludolph AC (2014) Live and let die: existential decision processes in a fatal disease. J Neurol 261:518–525

pubmed: 24413639 doi: 10.1007/s00415-013-7229-z

Weber C, Fijalkowska B, Ciecwierska K, Lindblad A, Badura-Lotter G, Andersen PM, Kuzma-Kozakiewicz M, Ludolph AC, Lule D, Pasierski T, Lynoe N (2017) Existential decision-making in a fatal progressive disease: how much do legal and medical frameworks matter? BMC Palliat Care 16:80

pubmed: 29284475 pmcid: 5745921 doi: 10.1186/s12904-017-0252-6

Dybwik K, Tollali T, Nielsen EW, Brinchmann BS (2010) Why does the provision of home mechanical ventilation vary so widely? Chron Respir Dis 7:67–73

pubmed: 20015913 doi: 10.1177/1479972309357497

Magelssen M, Holmoy T, Horn MA, Fondenaes OA, Dybwik K, Forde R (2018) Ethical challenges in tracheostomy-assisted ventilation in amyotrophic lateral sclerosis. J Neurol 265:2730–2736

pubmed: 30218178 doi: 10.1007/s00415-018-9054-x

Dybwik K, Tollali T, Nielsen EW, Brinchmann BS (2011) “Fighting the system”: families caring for ventilator-dependent children and adults with complex health care needs at home. BMC Health Serv Res 11:156

pubmed: 21726441 pmcid: 3146406 doi: 10.1186/1472-6963-11-156

Moglia C, Palumbo F, Veronese S, Group MNDIS, Calvo A (2023) Withdrawal of mechanical ventilation in amyotrophic lateral sclerosis patients: a multicenter Italian survey. Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol 44:4349–4357

Keller J, Gorges M, Horn HT, Aho-Ozhan HE, Pinkhardt EH, Uttner I, Kassubek J, Ludolph AC, Lule D (2015) Eye-tracking controlled cognitive function tests in patients with amyotrophic lateral sclerosis: a controlled proof-of-principle study. J Neurol 262:1918–1926

pubmed: 26041615 doi: 10.1007/s00415-015-7795-3

Update on recent advances in amyotrophic lateral sclerosis.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Subventions

Informations de copyright

Références

Auteurs

Nilo Riva (N)

Teuta Domi (T)

Laura Pozzi (L)

Christian Lunetta (C)

Paride Schito (P)

Edoardo Gioele Spinelli (EG)

Sara Cabras (S)

Enrico Matteoni (E)

Monica Consonni (M)

Eleonora Dalla Bella (ED)

Federica Agosta (F)

Massimo Filippi (M)

Andrea Calvo (A)

Angelo Quattrini (A)

Classifications MeSH